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 In vitro models are often used both to characterize and test therapeutics for 
neurodevelopmental disorders (‘NDDs’).  While in vitro models have extraordinary potential to 
develop therapies for patients, they have historically been confounded by absence of robust 
phenotypes and/or in vitro phenotypes that fail to translate from laboratory bench to bedside. 
Within this thesis work, we attempt to address three areas in which in vitro models may be 
improved – gene selection, model validation and identification of disease-relevant functional 
assays suited for therapeutic testing. 
 Publicly available databases aggregating identified and annotated disease-causing 
variants for Mendelian diseases have rapidly expanded over the past two decades. Elucidating 
mechanisms of disease and developing therapies using in vivo model systems often is both time 
and cost intensive. Thus, determining which subsets of genes are more likely to generate 
addressable signals in a dish may lead to more effective drug development. In chapter 1, we 
identify a set of genes ideally suited for therapeutic inhibition. Specifically, we leverage the 
aforementioned large genetic databases to identify a set of genes likely to act through a gain-of-




 In chapter 2, we aim to characterize the degree of conservation of transcriptomic 
dysregulation between a human in vitro cortical organoid (‘hCOs’) model, and two mouse 
models of a severe neurodevelopmental disorder resulting from HNRNPU deficiency. Human 
model systems may improve upon animal models when human pathogenesis and patient 
phenotypes are divergent from animal models due to species-specific etiology. However, human 
model systems often lack the heterogeneity and cell-type specificity and maturity seen in primary 
fetal samples. Importantly, some mouse models of HNRNPU deficiency have muted phenotypes 
compared with human patients. We hypothesized that while there are distinctions between 
humans and mice with HNRNPU deficiency, there will be overlap in transcriptomic 
dysregulation between human and mouse models. In fact, we find 45-day-old HNRNPU+/- hCOs 
have consistent transcriptomic dysregulation to embryonic mouse models, but not to perinatal 
mice. Our findings suggest hCOs are a viable model for characterizing HNRNPU deficiency; 
however, such models may only be appropriate for elucidating a transcriptomic disease state at a 
specific developmental time period. 
 Functional assays for neurodevelopmental disorders can aid in understanding whether 
transcriptomic dysregulation is relevant to patient symptoms, as genomic findings may not 
always correlate to disease-relevant phenotypes. Further, relevant functional phenotypes can then 
be utilized for testing potential therapeutics. Importantly, seizures are commonly present in a 
significant subset of neurodevelopmental disorders and seizure phenotypes have been described 
as driven by aberrant synchrony in neuronal networks. Using a multielectrode array platform, 
investigators can use a variety of computational methods to quantify aspects of synchrony in 
vitro. In chapter 3a, we introduce topological approaches capable of identifying novel synchrony 
phenotypes in primary neuronal networks from mouse models of neurodevelopmental disorders. 
 
 
Certain mouse models will be confounded by species-specific pathogenesis and/or vastly 
different developmental timelines and fail to generalize to human patients, motivating the need 
for functionally active and physiologically relevant human in vitro models. In chapter 3b, we 
attempt to generate human networks with balanced levels of excitation and inhibition and find 
confounding lack of functional maturation of inhibitory neuronal subtypes in 90-day-old stem 
cell-derived neuronal networks. Future work generating in vitro human neuronal networks with 
functionally mature inhibitory neurons would complement the findings in chapters 1 and 2 and 
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 The field of genetics has rapidly advanced in the two decades since the human genome 
project initially sequenced and analyzed the human genome (Hood 2013, Gibbs 2020). Over the 
past twenty years, researchers have identified a constantly growing list of disease-causing 
variants buoyed by the large numbers of genomes and exomes sequenced from both patient 
populations and unaffected individuals. However, identifying a gene that is implicated in, or 
even solely responsible for causing, a disease is only the first step towards both understanding 
the biological mechanism through which a variant can lead to patient phenotypes and developing 
therapeutics that actually impact lives. In order to move from genetic diagnosis to an effective 
treatment, we often require a model system that elicits a disease-relevant phenotype. Ideally, 
such a model system could also be used to test and validate therapeutic compounds. 
 Translating a genetic diagnosis to effective therapeutics can be challenging. Following 
the identification of causal variants, researchers often must identify an appropriate model system 
to further investigate pathogenesis and test therapeutic candidates. Discovering patient-relevant 
phenotypes in model systems may be especially difficult for neuropsychiatric diseases, given the 
complexity of the human brain and inability to ascribe many psychiatric symptoms to rodent or 
other non-human model systems. Such difficulties may partially explain why several studies 
have found that the success rate of progressing therapeutics from phase I to FDA approval for 
central nervous system (CNS) disorders lags the average across all indications, with an especially 
low success rate for therapies intended to treat psychiatric illness (table 1). The difficulties 
developing therapeutics for neuropsychiatric disease are underscored by considering the history 
of developing therapeutics for two well-studied and highly funded disorders, Alzheimer’s disease 
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and Fragile X syndrome (FXS). As of 2018, high failure rates of clinical trials contributed to the 
cost of developing an Alzheimer’s therapeutic being estimated at $5.6 billion, approximately 
seven times that of a cancer therapy (Cummings 2018). Similarly, a recent review described the 
two decades of research into FMR1, a gene known to cause FXS when silenced, as “the most 
comprehensive drug development programme undertaken thus far for a genetically defined 
neurodevelopmental disorder” (Berry-Kravis 2018). Despite such an undertaking, several 
therapies that show high efficacy in rodent models have failed to translate to humans (Yan 2005, 
Choi 2011, Robertson 2013). As such, there are still no FDA-approved therapies for FXS. 
 The work within this thesis aims to address some of the obstacles in developing effective 
therapeutics for neuropsychiatric disorders by focusing on gene selection, transcriptomic 
dysregulation and functional readouts in chapters one, two and three respectively. In chapter 1, I 
leverage publicly available databases of Mendelian disease in order to identify a subset of genes 
well suited to generate druggable signals in vitro. In chapter 2, I identify overlapping 
transcriptomic signatures in human cortical organoids and embryonic mouse cortices. The 
transcriptomic signature of disease was compared between a human stem-cell model and two 
mouse models of HNRNPU deficiency. Critically, perinatal mice had divergent transcriptomic 
signatures of disease, suggesting therapeutic stratagems may be confounded by the 
developmental time point of model systems. In chapter 3, I attempt to improve upon existing in 
vitro functional readouts of neuronal network activity that may be used to assess therapeutic 
efficacy. Specifically, chapter 3 aims to improve the capacity of existing in vitro mouse and 
human models to identify robust neuronal network synchrony phenotypes using multielectrode 
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The overarching goal of this work is to improve the ability to develop effective therapeutics 
for neurodevelopmental disorders (‘NDDs’) by focusing on identifying phenotypes in vitro that 
are relevant to human disease. Given the heterogeneity of NDDs and the complexities of the 
human brain, an efficient precision medicine approach to therapeutic development requires 
thoughtful gene selection, robust patient-relevant phenotypic readouts, and validation that 
phenotypes seen in vitro can be partially reproduced in an in vivo model system.  
1.1 Neurodevelopmental Disorders  
NDDs are, very broadly, any impairment in the development of the brain and central nervous 
system. Whether or not a specific disorder is considered neurodevelopmental is often debated. 
Certain adult psychiatric disorders, including schizophrenia and bipolar disorder, have been 
hypothesized to originate from early abnormalities in brain development (e.g., Owen 2011, Valli 
2019). Genetic studies have suggested common etiology between adult psychiatric disorders and 
more securely defined NDDs, such as Autism Spectrum Disorders (ASDs) (Owen and 
O’Donovan 2017). Organizations such as the International Stress and Behavior Society, have 
established a general framework for describing the most prominent NDDs and a broader ‘NDD+’ 
spectrum that incorporates adult psychiatric disorders such as Schizophrenia and Bipolar disease 
(figure 1, Homberg 2016).  
The NDD and NDD+ spectrum is a heterogenous group of disorders with a wide range of 
phenotypes that may range from intellectual disability to psychosis to high prevalence of 
seizures. For the remainder of this thesis, NDDs will refer to the broadest definition, spanning 
the NDD+ spectrum. It can be safely hypothesized that most NDDs by this definition are driven 
by a disruption to the normal processes of brain development. 
1.2 Biomarkers  
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Diagnoses of NDDs have historically been confounded by significant heterogeneity and 
comorbidity between distinctly defined disorders. Further, diagnosis of certain NDDs, such as 
Autism Spectrum Disorder, relies on identifying and reporting varied clinically defined autistic 
behaviors. Understanding the difficulties in appropriate and consistent diagnoses, the FDA and 
the NIMH have emphasized the need for a more complete understanding of neurodevelopmental 
disease that relies on the identification of biomarkers (Insel 2014). Biomarkers refer to any 
objective measurement observed outside of a patient and they may be especially impactful in 
generating therapeutics for patients suffering from NDDs. 
 Biomarkers can either come directly from patient samples or can be generated from 
disease-relevant model systems. Previous research has shown that certain biomarkers found 
within the blood and urine, or by measuring head circumference and digit ratio, correlate with 
less easily quantified phenotypes, such as stereotyped behavior and reported neurologic 
dysfunction (Bridgemohan 2019). While some biomarkers may be identified directly from 
patients or patient samples, often times disease-relevant biomarkers are inaccessible without 
using a model system. For instance, postmortem schizophrenic brains show upregulation of 
certain neuroinflammatory processes, but similar measurements are not currently possible in 
living patients (Trepanier 2016). 
 Often times, the etiology of disease is unknown, and a broad analysis of biological 
processes may be beneficial. One potential approach is to investigate the relative expression of a 
large number of genes in disease-relevant cell types to identify a set of dysregulated genes. RNA 
sequencing has been readily used for over a decade, but continuous technological advancements 
have allowed for more affordable, complex sequencing and computational analyses have 
similarly improved (Stark 2019). One of many recent sequencing innovations includes the ability 
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to perform single-cell RNA sequencing, allowing researchers to identify transcriptomic 
differences in specific subpopulations of cells (Tang 2019). In cancer research, both bulk RNA 
sequencing and single-cell RNA sequencing have been used to identify biomarkers and have 
already contributed to the development of effective therapeutics (Wang Y. 2020). Importantly, 
cancer research often assesses the transcriptome of tumor samples extracted directly from 
patients, while similar primary samples are typically inaccessible for NDDs. Thus, identifying 
biomarkers of disease in appropriate model systems may be especially necessary to develop 
therapies for patients with NDDs.   
1.3 Mouse Models of NDDs 
Preclinical studies for NDDs often rely upon model systems to identify disease phenotypes 
and test therapeutic compounds. A wide variety of animal models exist to study brain disease, 
ranging in size from the nematode, C. elegans, to non-human primates. Each animal model has 
certain benefits and limitations. Rodent models have long been the most commonly used model 
to study human disease due to a combination of large numbers of offspring, relatively short life 
span and relative ease of genetic manipulation due to both breeding strategies, and more recently, 
genome engineering.  Together this has generated a wealth of publicly available data on mouse 
genetics and previously characterized mouse models of disease (Bryda 2013).  
Within the Institute of Genomic Medicine (“IGM”) alone, we currently have more than 15 
genetic mouse models with mutations in genes known to cause NDDs. The basic paradigm to go 
from mouse model to clinical therapy relies on identifying a disease-relevant phenotype in 
mutant animals and then discovering a therapy that effectively rescues the phenotype in the 
mouse model. At that point, a therapy may be tested in humans to assess safety and efficacy. 
Every step of this process has a variety of challenges that may contribute to failure when 
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attempting to translate findings from mouse models to clinical therapies (figure 2). Perhaps the 
most prominent obstacle is the concern that certain pathogenic processes may be species-
specific. While the majority of protein-coding genes are shared between mice and humans, there 
remains significant genomic divergence in certain critical processes, including transcriptional 
regulation and chromatin remodeling (Yue 2014). 
In addition to potentially divergent biomarkers, mice may not exhibit symptoms similar to 
those seen in patients with similar genetic disruption. When considering a large number of 
mouse models of rare NDDs, Fallah and Eubanks identify certain genetic models with similarly 
severe seizure phenotypes to patients along with several others that fail to recapitulate prominent 
epileptic phenotypes seen in humans (Fallah 2020). 
Further, more complex neurological and behavioral phenotypes are often impossible to 
identify in a mouse. Common presentations of psychosis, including delusions of grandeur, manic 
episodes or obsessive attachment to unusual objects are impossible to directly assess in mice and 
therapies would rely on correcting alternative, accessible phenotypes. Importantly, biomarkers 
may allow for the identification of relevant, accessible phenotypes in certain instances. For 
example, while certain behavioral phenotypes are inaccessible in mouse models of Fragile X 
Syndrome or do not strongly recapitulate human disease, several biomarkers of disease are 
conserved across species (Dahlhaus 2018). The existence of consistent cross-species disruption 
suggests certain pathogenic mechanisms are conserved. Thus, mouse models have both clear 
potential and significant limitations.  
1.4 Human Stem Cell-Derived Neurons to Model Disease 
Recently, neurons derived from human pluripotent stem cells have emerged as a promising 
means to investigate a wide range of CNS disorders, including NDDs. Generation of human 
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neurons typically first requires the generation of pluripotent stem cells, cells capable of 
differentiating into all three germ layers – endoderm, mesoderm or ectoderm.  
Using both embryonic (‘ESCs’) and induced pluripotent (‘iPSCs’) stem cells, researchers 
have been able to generate specific neuronal subtypes from certain brain regions in vitro. Two 
frequently used mechanisms to generate brain cells from stem cells are 2D and 3D differentiation 
protocols (figure 3a). In 2001, early paradigms to generate neural precursor cells using 3D 
embryoid bodies and 2D low-density cultures emerged (Zhang 2001, Tropepe 2001). Several 
years later, Chambers et al. found that inhibiting SMAD signaling in 2D cultures led to highly 
efficient neural induction of human stem cells (Chambers 2009). While SMAD inhibition is not 
required to efficiently generate neural precursors, many subsequent 2D and 3D neural 
differentiation paradigms incorporate SMAD inhibitors (Galiakberova 2020).  
Over the past decade, both 2D and 3D models based on SMAD inhibition have shown the 
ability to generate cells specific to several brain regions (figure 3b,c), including the midbrain, 
hippocampus, hypothalamus, cerebellum and cerebral cortex (Logan 2019, Tanaka 2020). Brain 
organoid models have been used to model a wide array of phenotypes, including malformations, 
defective ion channels, protein aggregation, activity differences and neuronal cell death in a wide 
spectrum of diseases from developmental to degenerative CNS disorders (Wang 2018, Logan 
2019, Chang 2020, Sen 2020).  
Importantly the relative composition of neuronal subtypes is critical to maintaining healthy, 
functional neuronal networks. Within the cerebral cortex, a disruption in balance between two 
major subtypes, excitatory and inhibitory neurons, has been frequently hypothesized to underlie a 
wide spectrum of NDDs and neurodegenerative disorders (Lopatina 2019). Further, both 
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preclinical and clinical studies have shown evidence of disrupted excitatory/inhibitory (‘E/I’) 
balance in epilepsy and autism, which may underlie their frequent comorbidity (Bozzi 2018).  
Unfortunately, many 2D and 3D cortical differentiation protocols are heavily enriched for 
only excitatory or inhibitory populations or require fusion of organoids with unknown numbers 
of cells (e.g., Li 2009, Espuny-Camacho 2013, Nicholas 2013, Maroof 2013, Birey 2017, Xiang 
2017). In addition to the broad categories of excitatory and inhibitory neurons, many more 
specifically defined subtypes may be directly implicated in disease and absent from in vitro 
human neuronal populations. A robust comparison of the transcriptomes of 3D human cortical 
models and fetal tissue showed the neurons generated in model systems often cannot be cleanly 
associated with in vivo cellular subtypes (Bhaduri 2020). 
While such limitations are concerning, human-specific models of brain disease retain 
incredible promise. A recent study comparing human and non-human primate organoids, along 
with human and macaque primary samples, identified a large number of genes differentially 
expressed in humans that suggest species-specific developmental processes (Pollen 2019). Such 
species-specific processes are further pronounced when compared to rodent models. For 
example, cortical interneurons in the developing human neocortex are significantly more diverse 
than in rodents (Boldog 2018), and this complexity may underlie higher brain function (Zecevic 
2011). Thus, studying stem-cell derived neuronal cultures in vitro may be necessary to 
appropriately model a subset of NDDs that involve human-specific processes or neuronal 
subtypes.  
1.5 Cross-species transcriptomic comparisons  
Ensuring an in vitro model recapitulates critical elements of pathogenesis seen in patients is 
one of the significant challenges in developing treatments for NDDs. Identifying a biomarker or 
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a set of biomarkers in a single model may be informative to etiology or may be specific to the 
system being analyzed. In order to address this concern, researchers regularly seek to validate a 
finding in an alternative model system. The cross-validation of biomarkers between models can 
be done within the same species yet may be more robust when considered across species. Such 
cross-species comparisons are often used, with researchers identifying some elements of 
conserved pathogenesis in NDDs between human stem-cell derived neurons and mice (e.g., Nott 
2016, Shi 2019, Zhang W. 2020, Panov 2020). However, such comparisons typically assess a 
small number of biomarkers or only compare a singular biological process across species. 
Importantly, such correlated phenotypes may identify shared pathogenesis, but do not address the 
overall similarity of disease signature in different model systems.   
Broad transcriptomic analyses may allow for the identification of a large number of 
biomarkers that can then be compared across species. One potential approach involves using 
RNA-sequencing to compare all differentially expressed genes in a human and mouse model of 
the same or similar genetic perturbation. Such comparisons theoretically can be done using any 
of the in vitro human models discussed above. Nevertheless, to date, no existing research has 
shown concordant disease signatures across species. To this end, we hypothesized that 
comparing transcriptomic signatures between mice and cerebral organoids may either validate, or 
invalidate, the use of both models. Highly concordant disease signatures across species would 
suggest such biomarkers are robust and may be recapitulated in patients. Alternatively, 
discordant signatures suggest biomarkers generated from either one or both models are invalid or 
potentially specific to a particular neurodevelopmental time window or cellular subtype. 
1.6 Identifying Ideal Models to Study in vitro 
10 
 
Before attempting to identify cross-species transcriptomic comparisons in a mouse and 
human model of disease, it may be beneficial to consider genetic models particularly well-suited 
for in vitro characterization and eventual treatment. When characterizing certain aspects of 
NDDs in chapters 2 and 3a, we focus predominantly on autosomal dominant Mendelian 
disorders with known, pathogenic de novo mutations that are associated with severe NDDs. 
While such disorders will not always translate effectively to the in vitro models described below, 
in aggregate they may be less confounded by penetrance concerns and muted phenotypes. 
Autosomal dominant disorders can be due to either a gain-of-function (‘GoF’) or loss-of-
function (‘LoF’) mechanism. Many LoF mutations can often be characterized as 
haploinsufficient, meaning the mutant allele does not generate a functional protein; thereby, 
forcing your body to rely on a single healthy copy.  Alternatively, GoF mutations can fit into two 
broad functional categories, hypermorphic and neomorphic. Hypermorphic mutations are defined 
by variants that lead to excess functional protein (i.e., gene duplication), while neomorphic 
mutations cause a change in function. Surprisingly, the mode of action of many single disease-
causing genes is not known. Certain large databases of pathogenic variants, such as ClinVar, 
have gene lists annotated as likely haploinsufficient, but no corresponding annotations of likely 
GoF genes.  
 Identifying the direction of effect for a genetic mutation has implications for generating 
mutant models and for developing therapeutics. In aggregate, variants in haploinsufficient genes 
are less spatially clustered on the genome than non-haploinsufficient genes (Lelieveld 2017). 
Thus, generating patient-specific mutations for GoF genetic disorders is especially critical. 
Alternatively, in certain instances, nonspecific variants that lead to truncated proteins may 
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reasonably model LoF genetic disorders with more broadly distributed pathogenic variants, 
providing an important benefit for attempts to model haploinsufficiency in vitro. 
 While model generation may be easier for haploinsufficient Mendelian disease, drug 
development strategies would benefit from a priori knowledge of a likely GoF disorder. A 
significantly larger number of FDA approved therapeutics are inhibitors, instead of activators 
(Law 2014). Further, the use of inhibiting molecules, such as antisense oligonucleotides (ASOs) 
and RNAis, allow for additional mechanisms to inhibit GoF disease genes. Within the first 
chapter of this thesis work, we have developed a simple formula based on known pathogenic and 
likely pathogenic mutations in ClinVar to identify a large number of genes that are likely GoF 
and ideally suited for therapeutic inhibition. Alongside existing resources for identifying known 
haploinsufficient genes, such work allows for more efficient identification of mutations best 
suited to characterize, and attempt to treat, in vitro. 
1.6.1 Cross-species Transcriptomic signature for HNRNPU deficiency 
The work within the second and third chapters of this thesis aims to develop paradigms in 
vitro more likely to identify robust, disease-relevant molecular and cellular phenotypes. 
Identifying genes that are likely druggable with a known direction of effect helps streamline 
what disorders are best characterized in vitro. However, when selecting a Mendelian disorder for 
characterization, when and where the gene is expressed during development must also be 
considered. For example, during human neurodevelopment, PAX6, TBR2, and TBR1 are 
sequentially expressed as neural precursors develop into more mature neuronal subtypes 
(Englund 2005). Similarly, cortical interneuron precursors generated in the Medial Ganglionic 
Eminence express NKX2.1 early in development, followed by LHX6 during neurogenesis and 
migration, and Somatostatin (SST) and Parvalbumin (PV) at more mature stages (Lim 2018). 
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Further, many of the same developmental transitions seen in embryogenesis are often 
recapitulated with 2D and 3D neuronal differentiation paradigms in vitro (e.g., Chambers 2009, 
Maroof 2013, Lancaster 2013, Xiang 2017, Sloan 2018). Thus, transcriptomic states will be 
sensitive to developmental timepoint and neural subtype and careful consideration of neuronal 
maturity and cell-type specificity may be necessary to generate patient-relevant gene expression 
signatures in vitro.  
In chapter 2, we consider the transcriptomic dysregulation driven by disruption of one 
such gene, HNRNPU, known to be capable of causing a severe early onset NDD (Epi4K 
Consortium 2012, Hamdan 2014, Depienne 2017, Bramswig 2017). HNRNPU is the largest 
member of the heterogeneous nuclear ribonucleoproteins, a family of RNA-binding proteins 
(Geuens 2016). To date, 57 pathogenic or likely pathogenic variants have been identified in 
HNRNPU, an RNA/DNA-binding protein located on chromosome 1. The variants are 
predominantly protein-truncating and are dispersed throughout the gene, suggesting a LoF 
mechanism (figure 4c). Patients with deleterious de novo mutations in HNRNPU display severe 
phenotypes (figure 4a,b), with patients experiencing developmental delay, intellectual disability, 
seizures early in childhood and occasional microcephaly, among other phenotypes (Yates 2017, 
Bramswig 2017, Durkin 2020). Thus, HNRNPU-related disorders have an established direction 
of effect, are known to be highly penetrant and causal for a NDD and lead to significant 
morphological and functional phenotypes early in childhood.  
In addition to early phenotypes, as a DNA and RNA-binding protein and chromatin 
remodeler (Fan 2017, Poot 2018), HNRNPU is ideally suited for transcriptomic analyses due to 
its roles in directly and indirectly impacting the expression of a large number of genes during 
neurodevelopment.  HNRNPU’s role in embryonic development begins as early as at the stem 
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cell level, where it binds to the proximal promotor of OCT4, a transcription factor involved in 
maintaining and regaining stem cell pluripotency (Vizlin-Hodzic 2011). Importantly, HNRNPU 
is also widely expressed in the cerebral cortex in vivo in both humans and mice during 
neurodevelopment (Uhlen 2015, Human Protein Atlas, Allen Developing Mouse Brain Atlas 
2008). Thus, we posited that LoF HNRNPU variants in human stem cell-derived cerebral 
organoids and mice will lead to widespread transcriptomic changes that may be characterized 
and compared. 
1.7 Functional Phenotypes to Characterize NDDs in Mice 
Biomarkers, including transcriptomic signatures of disease, may be incredibly valuable in 
identifying elements of disease and therapeutics can be assessed based on whether or not they 
reverse disease-specific biomarkers in murine or human models. However, even if biomarkers 
are strongly correlated to disease, they may not be causal for phenotypes seen in patients with 
NDDs. Validating that any biomarkers are causal for disease may require the identification and 
reversal of a functional phenotype. A functional readout can very broadly describe any 
observable, quantifiable phenotype that describes a biological mechanism. Intuitively, reversing 
a functional readout can only ameliorate symptoms in patients if the readout has relevance to 
human disease and the mechanism for reversal in a model system is recapitulated in patients. 
Identifying disease-relevant readouts in model systems can be particularly challenging when 
considering neurological illness, as several definitive phenotypes such as psychosis, are 
inaccessible outside of patients. Promisingly, electrical activity phenotypes are often found in 
patients and are more likely to be tractable in both mouse and in vitro human models. 
Epilepsy refers to a chronic brain disorder characterized by recurrent seizures, which are 
driven by uncontrolled electrical activity and hypersynchrony in the brain. Epileptic 
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encephalopathies (EEs) are a group of disorders where such epileptic activity contributes to 
additional, severe cognitive and behavioral deficits (Jain 2013, Stafstrom 2016). While epileptic 
encephalopathies are not explicitly considered NDDs within the diagnostic and statistical manual 
of mental disorders, fifth edition (‘DSM V’), the prevalence of such disorders is significantly 
enriched within prominent NDDs including Intellectual Disability (22.5%), Autism Spectrum 
Disorder (20%) and ADHD (15%) compared to the general population (0.8%) (Shankar 2020). 
The general prevalence of epilepsy, along with known comorbidity with stereotypical NDDs 
allow for EEs to be investigated as a subset of the overall NDD landscape. 
Importantly, in vitro models of EEs may benefit from more tractable patient-relevant 
assays. The spectrum of patient phenotypes across the broader family of NDDs are highly 
heterogeneous and certain prevalent symptoms, such as behavioral abnormalities and intellectual 
disability, are inaccessible using in vitro models. Alternatively, NDDs with associated epilepsy 
definitively have neuronal activity and synchrony phenotypes that may potentially be reproduced 
in vitro. Thus, the functional analyses in chapter 3a only consider genetic disorders in which the 
vast majority of the patient population we are attempting to model have, or once had, seizures.   
1.7.1.1 Seizure Phenotypes in Mouse Models 
Critically, seizure phenotypes are not always robustly recapitulated in mouse models of 
EEs. While a direct correlate between functional phenotypes in mouse models and human 
patients is ideal, some mouse models do not robustly recapitulate the severity of patient disease. 
Colleagues within the IGM characterized a mouse model of HNRNPU haploinsufficiency where 
the mice have reduced seizure threshold, but do not experience spontaneous seizures, suggesting 
a milder phenotype than that of more severely impacted human patients (Dugger 2020). 
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 In addition to difficulties recapitulating patient seizure phenotypes, in vivo models cannot 
be characterized and screened for therapeutics with significant throughput. Even if we were to 
identify a functional readout that reliably describes mutant mice and correlates to human disease, 
identifying a therapeutic intervention may require testing of a significant number of compounds. 
While we cannot ensure a priori that correcting a phenotype in a mouse model will also lead to 
improved patient outcomes, we can improve the throughput by identifying, and potentially 
correcting, functional readouts using in vitro models. 
1.7.1.2 Multielectrode Arrays to Characterize Neuronal Network Dysfunction in Mice 
Seizures can broadly be described as either generalized or focal. Generalized seizures 
involve multiple brain regions, while focal seizures are isolated to just one region. Within each 
of these seizure subtypes, there also exists significant heterogeneity. The wide variety of 
symptoms that can be associated with seizures includes, among many others, confusion, 
excessive blinking, complete loss of consciousness, and muscle spasms. While seizure types in 
patients can often be clearly characterized and diagnosed, there is no consensus definition for the 
exact boundaries of brain network activity dysfunction that define a seizure more broadly.  
Hal Blumenfeld described one potential unifying description, where a seizure proper is an 
area of intense increases in brain activity readouts such as neuronal firing, with other areas 
showing a significant reduction in those readouts being defined as inhibited by the seizure 
network (Blumenfeld 2014). While such definitions are less important for in vivo models, they 
are important to consider when utilizing in vitro models. One potential prerequisite emerging 
from definitions in line with Blumenfeld’s is an in vitro platform that includes some capacity to 
measure the activity of a network of neurons.  
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An approach to study neuronal network activity in vitro includes utilizing multielectrode 
arrays (MEAs). Specifically, MEAs consist of some number of electrodes capable of capturing 
the local field potential or activity of a population of cells. MEAs can be used to quantify activity 
patterns of many cell types, including various types of neuronal populations. Importantly, 
researchers have previously optimized methods to extract neurons from embryonic or perinatal 
mice and allow neuronal populations to survive and form networks in vitro. Over the past two 
decades, scientists have maintained primary neurons from embryonic mice (Sciarretta 2010), 
extracted cortical, hippocampal and cerebellar neurons from newborn pups (Ahlemeyer 2005) 
and even cultivated healthy striatal neurons from adult mice (Eide 2005).  
Many distinct functional readouts can be assessed using primary neuronal cultures, 
including, among many potential assays, higher throughput analyses of electrophysiological 
phenotypes using MEAs. When considering modeling EEs in vitro, a network level 
electrophysiological phenotype may be appropriate for modeling widespread disruption of 
neuronal activity associated with disease. One potential paradigm for medium-throughput 
characterization and drug screening of mutant mouse phenotypes includes dissociating cortical 
neurons from perinatal wild-type and mutant mice and plating them at high density onto MEAs, 
followed by longitudinal recordings of electrical activity over several weeks (figure 5a).  
Importantly, using cortical primary cultures and MEAs to model aberrant neuronal 
network activity comes with significant drawbacks. Most prominently, any primary neuronal 
culture requires disrupting the three-dimensional structures of the brain. Further, there is no 
existing mechanism to generate an in vitro primary culture that includes all brain regions. Thus, 
any primary culture will have significant limitations and will rely on the capacity of the neuronal 
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subtypes being assayed to faithfully reassemble a functional neuronal network that recapitulates 
elements of the human disease in question.   
Generalized seizures definitionally involve both hemispheres of the cerebral cortex 
undergoing aberrant activity simultaneously. Further, focal cortical dysplasias, which are 
localized malformations of cortical development, are the most common cause of medically 
refractory EEs in pediatric patients (Kabat 2012).  Importantly, cortical networks in vivo are not 
a closed loop and interact directly or indirectly with other regions of the central nervous system. 
Some of these interregional networks have been directly implicated in a subset of epilepsies. 
Interactions between the cortex and striatum have been hypothesized as causal for EEs driven by 
disruptions in STXBP1 and SCN2A (Miyamoto 2019). Similarly, disruptions in cortico-
hippocampal and cortico-thalamic networks have been implicated in generalized seizures and 
temporal lobe epilepsy, respectively (Toader 2013, Ji 2015).  
In addition to the potential contribution of other brain regions to patient phenotypes, we 
must consider whether dissociated cortical neurons are fundamentally similar to their in vivo 
counterparts. To this end, researchers found that alongside certain compositional and 
spontaneous activity differences, in vitro primary cortical neurons on MEAs responded similarly 
to their in vivo counterparts when exposed to atropine yet were significantly more sensitive to 
ketamine treatment (Belle 2018). Further, investigators were able to reliably identify 
seizurogenic/neurotoxic compounds or better predict potential drug-induced seizure risk using rat 
cortical neurons plated on MEAs, suggesting MEAs may be suited to characterize epileptiform 
activity in vitro (Bradley 2018, Kreir 2018).  Given the limitations, MEAs importantly are 
buoyed by the potential for significantly higher throughput assessment of therapeutics. 
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Specifically, in a single 48-well plate, multiple drugs can be tested on wild-type and mutant 
primary mouse cultures and their responses to drug treatment can be characterized (figure 5b).  
1.8 Synchrony 
Synchrony in neural networks can very broadly be described as correlated activity between 
any two populations of cells. Such synchrony can be as broad as comparing patterns of activity 
between two distant brain regions or as specific as comparing how frequently two individual 
neurons are active at the same time (figure 6a). Through the 20th century and into the 21st 
century, epilepsy was predominantly defined by abnormally high neuronal firing and highly 
synchronized activity. More recently, patterns of both increased synchrony and desynchronized 
activity have been implicated in the generation and termination of seizures (Jiruska 2013). Two 
prominent patterns of abnormal activity in epileptic patients, spike-and-wave discharges 
(‘SWDs’) and hypsarrhythmia, display characteristic patterns of increased and decreased 
synchrony respectively (figure 6 b,c).  
Disruption in synchrony phenotypes have also been found prominently in NDDs more 
broadly. Reduced synchrony between cortical hemispheres has been identified in toddlers with 
ASD, while disruption of synchronous oscillations has been hypothesized to underlie the 
pathophysiology of Schizophrenia (Dinstein 2011, Uhlhaas 2011). Further, disruptions to neural 
synchrony have been identified in neurodegenerative disorders such as Parkinson’s and 
Alzheimer’s, in addition to a heterogeneous set of NDDs (Ulhaas 2006). Reliably identifying 
synchrony phenotypes in vitro may be broadly applicable to studying neurological disease, 
including NDDs and potentially neurodegenerative disorders as well. 
1.9 Synchrony in vitro 
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In both humans and rodents, the cerebral cortex exhibits highly synchronized network 
activity in prenatal and early postnatal time periods, with such synchronized activity also present 
in in vitro rodent models (Khazipov 2006). In vivo, murine neocortical networks transition to a 
much more desynchronized state in the second postnatal week (Golshani 2009). Alternatively, in 
primary cultures, dissociated mouse cortices maintain highly synchronized activity as they 
mature in vitro, with neuronal networks continuing to fire in highly synchronized patterns, where 
often all electrodes show simultaneous, high frequency activity (Segev 2001, Van Pelt 2004, 
Chen 2006). Within chapter 3a, I posit that this pattern of synchrony across electrodes may be a 
confounding variable that limits our ability to reliably identify synchrony phenotypes in vitro. 
Given the prevalence of synchrony phenotypes in neurological disorders and epileptic 
encephalopathies in particular, identifying and reversing synchrony phenotypes in vitro may lead 
to more efficient generation of therapeutics. However, such an approach critically relies on the 
ability to identify aberrant synchrony in vitro. To this end, our institute and the Eglen lab 
developed a computational package, meaRtools, to analyze MEA data (Gelfman 2018). Within 
meaRtools, several distinct measures of synchrony exist, ranging from pairwise electrode-based 
analyses such as Mutual Information and Spike-Time Tiling Coefficient to population wide 
measures including Network Spikes and Network Bursts (figure 6d). Each of these algorithmic 
measures aim to characterize distinct features in vitro that may model some aspect of synchrony 
seen in human brains. The diversity of approaches to characterize synchrony in vitro may allow 
for identification of distinct synchrony phenotypes across models, given the significant 
heterogeneity in patterns of aberrant synchrony seen in the EEGs of patients with EEs (e.g., 
Smith 2005, Bui 2015, Wenzel 2019). Despite the diversity of approaches, there often remain 
significant challenges identifying in vitro synchrony phenotypes. For example, colleagues within 
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the IGM identified in vivo ECT phenotypes for both heterozygous and homozygous mutant mice 
with a knock-in mutation of a patient-specific variant within GRIN2A, but no significant in vitro 
phenotypes were identified in the heterozygous mutant mice (Amador 2020).  
We hypothesized that the continued high levels of synchrony in vitro may be confounding 
and require more complex computational approaches for the identification of aberrant synchrony 
inaccessible using existing metrics. To that end, we incorporated measures of distance to existing 
measures of synchrony in order to generate novel, synchrony measures higher granularity that 
are able to identify different types of synchrony in developing primary neuronal networks.  We 
test these new measures utilizing three distinct mouse models of EEs. 
1.10 Synchrony in vitro in human models 
Similar to the identification of biomarkers, functional readouts may benefit from cross-
species comparisons to validate phenotypes are not predominantly species- or model-specific. 
Importantly, the balance of excitation and inhibition is heavily implicated in a wide array of 
neurological disorders. Further, excitatory and inhibitory activity-dependent processes have been 
found to be critical to the maturation of cortical networks (Chattopadhyaya 2011, Lehman 2012, 
Pan 2019). Thus, generating neuronal networks in vitro with physiological proportions of 
excitatory and inhibitory neurons may allow for the identification of disease-relevant synchrony 
phenotypes in vitro in more functionally mature networks. Similarly, assessing synchronicity in 
excitatory enriched, inhibitory enriched and more physiological neuronal networks may 
contribute to the understanding of etiology of diseases driven by E/I imbalance.  
1.11 Research strategy and specific aims 
Developing and validating paradigms to effectively model neurodevelopmental disease may 
be a critical step in generating therapeutics that impact the lives of patients. Within this thesis, I 
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propose an approach that goes from bedside to a dish and, hopefully, back to bedside. Each 
chapter within this work aims to address a potential limitation in generating effective 
therapeutics for a broad spectrum of NDDs. In previous reviews and meta-analyses, researchers 
have robustly described the large number of obstacles impacting the field’s ability to effectively 
model and treat brain diseases, including developmental disorders (figure 7). Alternatively, 
advances in stem cell biology, electrophysiological techniques, sequencing capacity and 
expanding databases of Mendelian disease variants and annotations have set the stage for 
dramatic improvement in disease modeling and therapeutic development in vitro. The work 
discussed herein addresses a small subset of the many obstacles and opportunities in search of 
developing therapies for patients suffering from NDDs using in vitro models.  
In the first chapter of this thesis work, I aimed to identify a list of genes ideally suited for 
therapeutic inhibition. Importantly, prioritizing a targeted set of input genes may streamline drug 
development. While the direction of effect of certain disease-causing genes may be known, many 
rare or less well-studied autosomal dominant disorders have not been characterized as driven by 
a GoF or LoF mechanism. Identifying a direction of effect for such genes that additionally are 
tolerant to loss-of-function mutations and are known to be accessible with FDA-approved drugs 
may potentially streamline therapeutic development. Critically, the databases I utilize to identify 
tractable GoF genes are rapidly expanding and additional candidate genes are likely to be 
identified by refreshing the analyses on an annual basis. Importantly, therapeutic development 
strategies still require an appropriate model system capable of generating disease-relevant 
phenotypes. For neurodevelopmental disease, such model systems are often lacking and chapters 




In chapter two, I aim to identify a shared transcriptomic signature of HNRNPU deficiency 
across species. Historically, therapeutics for neurological disease developed using mouse models 
have met with limited success. Single-cell RNA-sequencing of human and mouse cortices 
identified well conserved cellular architecture between species, while also noting cell-type 
specific differences and alterations in morphology, proportions of cellular subtypes and gene 
expression (Hodge 2019). With evidence of significant similarities and differences, I 
hypothesized that cross-species comparisons of disease signatures could provide important 
information on etiology. Further, transcriptomic signatures shared across in vivo mice and human 
stem cell-derived neurons may more reasonably be expected to be conserved in patients, since 
they are replicated across species and distinct model systems. While mouse models suffer from 
species differences, individual 2D and 3D in vitro human models do not have the full diversity 
and specificity of cell types seen in vivo. Thus, many existing human and murine models of 
disease have the potential to elicit model specific phenotypes and may not effectively model 
certain NDDs. When comparing the transcriptomic signature of HNRPU deficiency of day 45 
cortical organoids to embryonic mice, we find shared dysregulation across models. However, the 
concordant disease signature is specific to an embryonic time point and not replicated in 
perinatal mice, suggesting the age and maturation of human models and human patients must be 
carefully considered when using such organoid or mouse models for therapeutic development.  
While identifying transcriptomic disease signatures more likely to be replicated in patients 
improves our understanding of pathogenesis and generates a phenotype that can be screened for 
potential therapeutics, functional readouts will often be necessary to validate drug candidates. 
Even if a compound is known to reverse some elements of transcriptomic dysregulation, the 
downstream symptoms patients experience may not be addressed. To this end, chapter three 
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focuses on improving the capacity of MEAs to identify aberrant synchrony in vitro in epileptic 
encephalopathies. MEAs are capable of longitudinal electrophysiological analyses of both 
primary cultures, including primary murine cortices, and human stem cell-derived neurons. 
Existing protocols for primary cultures suffer from high levels of synchrony in control cultures, 
resembling spike-and-wave discharges seen in epileptic patients, which may underlie limited 
success in utilizing MEAs to model and treat EEs. Human models provide species-specificity but 
often lack the diversity of neuronal subtypes seen in vivo and undergo protracted development. 
In chapter 3, I increase the sensitivity of murine MEAs to identify synchrony phenotypes in 
mutant networks using topology-based analyses that may help in identifying and reversing 
elements of epileptiform activity in vitro. I then attempt to generate human models with 
physiological proportions of major neuronal subtypes to generate more mature, physiologically 
relevant networks. However, existing differentiation paradigms of human excitatory and 
inhibitory models, when combined or allowed to mature independently, reliably generate certain 
canonical markers of neuronal progenitor subtypes, yet their synaptic profiles and activity 
profiles suggest lack of functional inhibitory subtype specificity in three-month-old neuronal 
networks, regardless of the composition of progenitors plated. 
Overall, this thesis work illustrates the outlines of a paradigm to effectively develop therapies 
for NDDs in vitro. I suggest an approach that relies on identifying genes most likely to generate 
addressable signals in vitro, elucidating disease-relevant biomarkers in appropriate model 
systems and engaging with functional readouts of synchrony in both mouse and human model 







Table 1: Approval rate of Phase I therapeutic candidates. Table aggregates four 
different attempts to quantify what percentage of drugs are eventually approved by 
indication after entering Phase I trials. Historically, success rates for CNS disorders lag 
other indications. When drugs for psychiatric conditions have been independently 
considered, such therapies have a lower likelihood of success than CNS disorders more 



















Figure 1: Spectrum of neurodevelopmental disorders. A depiction of the broader 
spectrum of neurodevelopmental disorders, including psychiatric disorders with 
evidence developmental trajectories (From Homberg 2016). ASD – Autism spectrum 
disorder. ID – Intellectual disability. CD – communication disorder. ADHD – Attention 
deficit disorder. TSC – Tuberous sclerosis complex. TD – tic disorders. MD – motor 
disorders. ME – Microcephaly. LE – Linescephaly. BD – Bipolar disorder. SZ – 
Schizophrenia. FAS/FASD – Fetal alcohol syndrome and spectrum disorders. ARND – 








Figure 2: From mouse to man; the challenges along the way. Challenges of developing 
therapeutics with mouse models start with successful generation and colony expansion of 
mice with specific mutations. Once a mouse model is generated, identifying human disease-
relevant phenotypes is often not straightforward. Even if robust, disease-relevant phenotypes 
are identified, throughput of drug testing and translating therapy for human delivery and 





  Figure 3: 2D and 3D stem cell paradigms to study the human brain. a) example schematic 
for generation of neurons using 2D monolayers (top) or 3D organoids (bottom). b) Cell types 
generated using iPSC-derived 2D monolayer cultures (Logan 2020). c) 3D organoid systems 





Figure 4: HNRNPU haploinsufficiency. a) Literature review of phenotypes commonly seen in 
patients with pathogenic HNRNPU mutations (table from Durkin 2020). b) Images of patients 
with pathogenic HNRNPU mutations (images from Yates 2020). c) All pathogenic and likely 
pathogenic mutations in ClinVar as of July 16, 2021 with mutation type listed. PTV = protein 





Figure 5: Multielectrode array paradigm for drug development – a) Illustrative workflow. P0 
mouse cortices plated into wells of 48-well MEA plate. Electrical recordings of electrodes 
allow for noninvasive acquisition of activity from several regions of a network of neurons. 
Each line in raster represents an action potential identified at a given electrode. b) Drug 
Dosing. At any point in an MEA experiment, multiple therapies can be added into well on a 





Figure 6: Modeling aberrant neural synchrony in vitro. a) Description of some ways to assess 
neural synchrony in vivo. Synchrony may be assessed between brain regions (left), within a 
brain region (middle) or between individual neurons or sets of neurons (right) using 
electroencephalography (EEG). b) Example of a spike-and-wave discharge seen on EEG in 
epileptic patients, where several groups of neurons are hyperactive simultaneously. c) 
Example of a hypsarrhythmic EEG seen in epileptic patients, where activity is excessively 
desynchronized and activity across sets of neurons is disordered. d) Using in vitro models to 
assess synchrony.  Activity patterns of distinct electrodes in MEAs can be analyzed using a 





Figure 7: Challenges and opportunities for CNS therapy development. a) From Vadodaria 
2018, underscores some strengths and limitations of using in vitro systems, rodent models, 
genome wide association studies (GWAS) and functional neuroimaging of patients. b) From 
Pankevich 2014, a detailed look at many confounding factors for developing CNS therapies 
alongside some potential avenues for progress. Amongst obstacles described are lack of 
identified biomarkers, animal models’ potential inability to recapitulate patient disorders and 
heterogeneity of population affected by nervous system disorders. Amongst opportunities 
described are validation of targets using multiple models and use of stem cell-based models. 7 
years later, using some of the previously described opportunities, we attempt to address a 




Chapter 1: Using reported pathogenic variants to identify 
therapeutic opportunities for likely gain-of-function genetic diseases 
Introduction 
Determining whether a genetic disorder is due to a gain, loss or change of protein function is a 
critical first step in effective drug discovery. For many recessive disease genes, including many 
inborn errors of metabolism, pathogenic variants have been clearly identified as loss of function. 
Similarly, for a number of dominant disease genes, careful functional characterization of variants 
found in patients has provided clear evidence of direction of effect.  For example, dominant 
pathogenic variants in the NSD1 gene have been shown to reduce or eliminate the function of 
NSD1 (Choufani 2015, McLelland 2016), whereas nearly all apparently pathogenic variants in 
SCN8A and KCNT1 have been clearly shown to be variants that increase channel current (Lopez-
Santiago 2017, Milligan 2014, Pan 2020, Quraishi 2019).  Furthermore, some disease genes have 
been clearly shown to carry both pathogenic gain of function and loss of function variants. For 
instance, after the identification of loss of SMCHD1 function as causative for a form of muscular 
dystrophy (Lemmers 2012), later research identified gain-of-function variants in SMCHD1 as 
responsible for a rare syndrome, BAMS (Gurzau 2018), a distinct genetic disease.  Overall, 
although many recessive genes are classified as due to loss of function (LoF) variants, and a 
subset of dominant genes are classified as haploinsufficient, meaning that disease is due to loss 
of activity of one of the two alleles, many dominant genes remain not clearly classifiable as due 
to predominantly either loss or gain of function variants. The secure identification of which of 
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these unclassified genes cause disease because of variants that increase or change the activity of 
the encoded protein would have immediate implications for drug development.   
 
Over the past decade, a wide range of approaches have been used to infer the functional impact 
of pathogenic variants (Dong 2014, Liu 2015, Li 2019). Attempts to identify LoF and GoF 
variants have leveraged existing bioinformatic tools like genetic tolerance sorting (SIFT), 
polymorphism phenotyping (PolyPhen) and conservation based Hidden Markov Models 
(Flanagan 2010, Liu 2014). Additionally, highly supervised approaches that manually examine 
variants suggested to be GoF within OMIM have been attempted (Chen 2017).  Despite these 
advances, identifying a subset of genetic diseases well suited for therapeutic inhibition has yet to 
be well established.  Surprisingly, no one has yet attempted to use the distribution of reported 
pathogenic variants to infer whether pathogenic variants are strictly gain or loss of function, or 
some combination.  The intuition behind this approach is straightforward. Genome wide it has 
been estimated that approximately 20% of missense variants are significant hypermorphic or loss 
of function variants (Kryukov 2007). In addition, on average, the proportion of variants in a 
human gene that are missense versus nonsense variants has been estimated to be about 1.05 
(Gorlov 2006). This means that for genes that cause disease due to haploinsufficiency, the 
proportion of pathogenic missense to all missense and LoF variants should be approximately 
0.21. This intuition is clearly supported by considering the well-known examples of NSD1 and 
KCNT1.  Of all reported pathogenic (mostly de novo) variants in NSD1, the proportion of 
missense variants is 0.27 (88 missense, 242 LoF), whereas KCNT1 has 38 reported pathogenic 
missense variants and no known pathogenic LoF variants. Based on this intuition, we have 
developed an evaluation of the proportion of variant type in all autosomal dominant genes in 
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order to infer the direction of effect of pathogenic variants.  Specifically, we seek to find a 
threshold on the proportion of variants that are missense versus LoF that is diagnostic of whether 
the gene causes disease due to loss or gain of function / hypermorphism. For convenience, 
hereafter, we will refer to both the gain of function and hypermorphism as “gain of function” 
(GoF), without attempting to distinguish between the two.  
 
Methods 
To develop a pipeline to distinguish genes that cause disease due to LoF or GoF, we first 
extracted all pathogenic and likely pathogenic (‘P/LP’) variants from ClinVar’s GRCh37 weekly 
VCF file with minor allele frequencies of 0 in all three of ExAC, GO-ESP and GMAF (figure 
1.1). We hypothesized Autosomal Dominant variants will predominantly cause disease via 
haploinsufficiency or GoF. Thus, we focused our analyses on known Haploinsufficient genes 
(n=361) and OMIM annotated autosomal dominant (“AD”) genes (n=219).    
 
 We then categorized variants as “likely LoF” if they were annotated as “nonsense”, “frame-
shift” or “stop-loss” and as “missense” if they were annotated as “missense.” All other variant 
types were not binned as either missense or likely LoF variants and were not include in ratio 
calculations. On the occasions where the same variant was annotated as both “likely LoF” and 
“missense,” the variant was excluded from downstream analyses. 
 
To assess whether the variant ratio is generally diagnostic of how variants caused disease, we 
first considered a set of genes that have been defined previously as haploinsufficient. To this end, 
we leveraged two separately generated lists of genes. First, we considered a list of genes 
35 
 
(“Dang”) generated through Dang et al.’s robust database-mining of OMIM and PubMed (Dang 
2008). We additionally considered ClinGen’s manually curated and reviewed list of 312 genes 
(“ClinGen”) determined to have “sufficient evidence of haploinsufficiency.” Out of these gene 
lists, a total of 361 unique haploinsufficient (“HI”) genes had more than 10 P/LP variants. Genes 
with fewer than 10 variants were not considered in any downstream analyses. Of these 361 
entries, 93 were shared, 63 were unique to Dang and 205 were unique to ClinGen. We 
considered both lists in order to identify a threshold on the variant ratio for autosomal dominant 
genes not annotated as haploinsufficient. Noting that genes that cause more than one Mendelian 
disease can have different directions of effects for different diseases, we also separately 
distinguished genes responsible for only one Mendelian disease.  
 
Results 
Autosomal Dominant Genes Enriched for Missense Variants 
In all genes considered (HI = 361, OMIM autosomal dominant, ‘AD’, = 219), we identified 
pathogenic or likely pathogenic variants classified as either missense or LoF (figure 1.1).   We 
first evaluated the ratio of missense to all pathogenic variants for HI genes that are associated 
only with a single Mendelian disease (figure 1).  We found that for known HI genes associated 
only with a single Mendelian disease, 95% of all HI genes have a missense ratio less than 0.8 
(128/135) and the median missense ratio for all haploinsufficient genes is 0.22, nearly identical 
to the a priori predicted ratio of missense variants. Importantly, since the generation of Dang’s 
list of HI genes, more recent research has clearly demonstrated haploinsufficiency is not the 
predominant mechanism of disease for variants of, MYOC and SH3BP2, while additional 
pathogenic GoF or dominant-negative variants have been identified in KCNQ4 and SLC40A1 
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(Kim 2001, Kamada 2006, Shepard 2007, Reichenberger 2012, Zhang 2019). Further, the three 
HI genes from ClinGen surpassing a threshold of 0.8 (OTC,PGK1,SMS) are all found on the X-
chromosome. Importantly, a simple threshold may identify more false positives when the total 
number of variants is lower. Thus, we alternatively considered the lower bound of a 95% 
binomial confidence interval and did not find a significant enhancement of signal (supplementary 
figure 1.1). Given similar results when considering a binomial lower bound and the successful 
exclusion of haploinsufficiency, we determine a simple threshold is sufficient to exclude 
haploinsufficiency as a likely mechanism for AD genes.  
 
Based on this finding, we considered all AD genes not known to be HI that are associated with 
only a single Mendelian disease, and we find 51 out of 110 applicable AD genes that appear to 
cause disease through GoF. Among this set of genes with variant ratios indicative of GoF, we 
find genes well known to cause disease due to GoF, such as GFAP and RIT1 (figure 1.2a).  
 
We then investigated whether or not our HI- threshold could be extended to all genes with at 
least one disease annotated as AD, including those that cause multiple Mendelian conditions. We 
found similar enrichment of AD genes and absence of HI genes above our threshold (figure 
1.2b).  Using our HI- threshold and more permissive inclusion criteria, we identified 124 AD 
genes (supplementary table 1.1) likely to act predominantly through gain-of-function. 
Importantly, we find the presence of aforementioned known GoF genes such a KCNT1 and 




Finally, we sought to examine the topological distribution of missense variants in GoF AD 
genes, given GoF variants in the aggregate tend to be more spatially clustered (Lelieveld 2017). 
As hypothesized, AD genes tended to be more clustered than known HI genes and autosomal 
recessive OMIM genes (supplementary figure 1.2). However, the distributions of clustering were 
overlapping and a clear way to incorporate clustering to complement a simple missense threshold 
was not apparent.  
Identifying GoF Genes for Drug Targeting  
Once we generated a threshold capable of reliably identifying likely GoF genes, we aimed to 
determine a subset of genes well suited for therapeutic inhibition. To assess whether inhibition is 
likely to be well tolerated, we considered whether the genes are under strong selection against 
loss of function variants using ExAC’s probability of loss of function score, pLI (Lek 2016). To 
this end, we only considered GoF genes highly tolerant to loss of function variants if they had a 
pLI score less than 0.1.  
 
When considering all AD and HI genes, lower pLI scores are correlated with increasing ratio of 
missense variants. However, the strength of correlation is minimal. Further, the distributions of 
AD genes and HI are not cleanly distinguished and 11 of the 35 genes with pLI<0.1 are known 
HI genes, including two genes, PKD2 and TRAPPC2, that are found in both HI sources (figure 
1.3). Thus, the addition of pLI is not redundant and complementary to our missense ratio 
threshold. 
 
Amongst the AD genes that appear to act through a GoF based on missense ratio, we identified 
36 genes that show no evidence of strong selection against loss of function variants in the human 
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population. Finally, we manually cross-referenced our list with “The Drug Gene Interaction 
Database” (Cotto 2018) to identify a set of genes known to be therapeutically accessible. 




Identifying causal GoF disease genes tolerant of reduced dosage would provide therapeutic 
targets of immediate interest. Further, publicly available drugs are more often inhibitors than 
activators, suggesting enhanced therapeutic potential for downregulation (Law 2014). Identifying 
likely GoF genes has proved relatively difficult, as displayed by the distribution of pLI scores for 
known Haploinsufficient genes and significant reduction in performance of Polyphen and SIFT 
compared to prediction of LoF variants (Flanagan 2010). Despite these difficulties, several 
groups have developed methods to identify likely GoF variants, but a definitive list of GoF genes 
remains elusive. Here, we leveraged the increasing number of known pathogenic / likely 
pathogenic variants to generate a HI- threshold that identifies likely GoF genes. We further 
parsed these likely GoF genes to identify a subset of targets that were both therapeutically 
accessible and LoF tolerant.  
 
Well characterized GoF genes, such as SCN8A, SOS1 and KCNT1 are present in the list of likely 
GoF genes, alongside mischaracterized “known haploinsufficient genes” like MYOC and 
SH3BP2. However, these genes all have been relatively robustly assessed in vitro, while many 
pathogenic variants have very limited functional evidence in the literature and can benefit 
particularly from a hypothesis on functional mechanism. Further, our list of likely GoF genes 
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with low pLIs includes GFAP, which when targeted with antisense inhibition, has shown the 
potential benefit of utilizing drug inhibition on candidate genes (Hagemann 2018).  
 
Importantly, within our analyses, we did not attempt to distinguish between hypermorphic 
variants and other GoF mechanisms. Similarly, we did not consider whether or not a variant may 
act through a dominant negative mechanism. Such genes may be present within our GoF list and 
additional strategies would be required to confidently exclude them.  
 
Finally, as publicly available datasets continue to increase in size, the list of genes with more 
than 10 variants that surpass HI- threshold will continue to increase. Thus, the list of 
therapeutically accessible likely GoF genes will expand and may provide important context when 
considering which treatment candidate to prioritize in vitro when investigating novel causal 
variants. Further, recent work from our lab and others has leveraged published RNA-sequencing 
data to identify downregulators of gene targets (Wang X. 2020, Shukla 2020). A similar 
approach in this context would be complementary and may lead to rapid successful drug 



















Figure 1.1. Identification of non-HI threshold.  a) Schematic describing set of 
haploinsufficient genes used to assess potential of missense ratio to exclude 
haploinsufficiency as likely mechanism of disease. All pathogenic/likely pathogenic 
variants with minor allele frequency of 0 were used to generate a ratio of missense 
variants for known haploinsufficient genes associated with a single OMIM disease. 
b) Box plot generated for known HI genes separated by source with median ratio 
values displayed. Overlap genes are in both ClinGen and Dang. c) Histogram of all 
















Figure 1.2: Identifying likely GoF AD genes. The relative frequency of missense ratios for known HI 
and AD genes are displayed alongside annotations of notable genes. Enrichment of AD genes with 
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Figure 1.3: pLI threshold complementary to non-HI threshold. a) Scatter plot with linear 
regression line of pLI versus missense ratio. Likely GoF genes tolerant to LoF variants shown 
in red box. Boxplots show distributions of pLI scores for known AD and HI genes, alongside 













pLI Score Druggable? 
ABCC9:10060 22 3 0.95 0.77 9.4E-09 Y 
APP:351 18 2 1 0.81 0.047 Y 
AVP:551 17 1 0.88 0.64 0.074 Y 
COMP:1311 45 2 0.93 0.82 1.3E-09 Y 
ELANE:1991 29 2 0.93 0.77 0.0012 Y 
FN1:2335 15 2 1 0.78 0.0014 Y 
KCNA1:3736 21 1 0.95 0.76 0.076 Y 
KCNT1:57582 38 2 1 0.91 2.8E-05 Y 
LRRK2:120892 10 1 0.8 0.44 2.6E-30 Y 
NOD2:64127 12 3 0.83 0.52 2.0E-30 Y 
PCSK9:255738 16 2 0.87 0.62 2.7E-17 Y 
PIK3R2:5296 11 1 0.81 0.48 0.016 Y 
TNNT2:7139 47 4 0.91 0.80 0.0020 Y 
TRPC6:7225 13 1 0.92 0.64 3.0E-07 Y 
TRPV4:59341 55 11 0.98 0.90 2.2E-16 Y 








Table 1.1: GoF genes suitable for therapeutic inhibition.  All genes have missense ratios >0.8, 
pLI <0.1 and are in the druggable genome. Number of known OMIM Mendelian diseases listed 













Supplementary figure 1.1: 95% Confidence interval (‘CI’) of missense ratios. a) Distribution 
of missense ratios for known haploinsufficient genes (Dang + ClinGen) and non-overlapping 
OMIM autosomal dominant genes. b) Lower bound of 95% CI using binomial distribution. c) 













Supplementary figure 1.2: Spatial clustering of missense mutations. 
Geometric mean distance of missense variants for known 
haploinsufficient (‘HI’), autosomal recessive (‘AR’), autosomal dominant 
(‘AD’) and autosomal dominant genes with missense ratio > 0.8 
(ADGoF). Distances are normalized by gene length and only unique 
mutation locations considered (e.g if two mutations at same locus, but 
distinct nucleotide substitution, only one variant considered). AR genes 
are HI- and AD-. AD genes are HI- and AR-. A small number of genes had 
more than 50 missense variants (n = 1 AD, 17 ADGOF, 8 AR, 54 HI). As 









LoF Variants Missense Variants Missense Ratio #OMIM Diseases 
ABCC9 22 1 21 0.95  3 
ABL1 30 0 30 1.00  2 
ACTA2 12 0 12 1.00  3 
ACTB 55 5 50 0.91  2 
ACTG1 32 0 32 1.00  2 
ACTG2 24 0 24 1.00  1 
ACTN1 19 0 19 1.00  1 
ACVR1 11 0 11 1.00  1 
APP 18 0 18 1.00  2 
ATL1 33 4 29 0.88  2 
ATP1A3 79 1 78 0.99  3 
AVP 17 2 15 0.88  1 
BICD2 20 0 20 1.00  2 
C1R 10 0 10 1.00  1 
CACNA1C 18 1 17 0.94  3 
CALM1 11 0 11 1.00  2 
CARD14 11 1 10 0.91  2 
CAV3 11 1 10 0.91  5 
CBL 10 1 9 0.90  2 
CDC42 12 0 12 1.00  1 
CDK13 15 3 12 0.80  1 
CHD3 20 2 18 0.90  1 
CHD4 14 1 13 0.93  1 
CHN1 10 0 10 1.00  1 
CLCN4 19 1 18 0.95  1 
COL4A1 63 6 57 0.90  5 
COL5A2 10 2 8 0.80  1 
COMP 45 3 42 0.93  2 
CSNK2A1 14 2 12 0.86  1 
DNAJB6 11 0 11 1.00  1 
DNM1 25 1 24 0.96  1 
DYNC1H1 65 0 65 1.00  3 
EEF1A2 16 0 16 1.00  2 
ELANE 29 2 27 0.93  2 
EZH2 29 3 26 0.90  1 
FBN2 31 2 29 0.94  2 
FGFR2 89 2 87 0.98  14 
FN1 15 0 15 1.00  2 
G6PD 26 1 25 0.96  2 
GABRA1 27 1 26 0.96  3 
GABRB2 20 0 20 1.00  1 
GABRB3 25 0 25 1.00  2 
GARS1 18 1 17 0.94  2 
GFAP 105 2 103 0.98  1 
GJA3 15 1 14 0.93  1 
GJA8 21 1 20 0.95  1 
GLUD1 12 0 12 1.00  1 
GNAO1 35 1 34 0.97  2 
GNB1 15 0 15 1.00  2 
HCN1 16 1 15 0.94  2 
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HECW2 13 0 13 1.00  1 
HNRNPA1 19 0 19 1.00  2 
IFIH1 37 3 34 0.92  2 
IKZF1 13 2 11 0.85  1 
INF2 23 0 23 1.00  2 
KCNA1 21 1 20 0.95  1 
KCNA2 15 1 14 0.93  1 
KCND3 12 0 12 1.00  2 
KCNH1 17 0 17 1.00  2 
KCNJ2 38 4 34 0.89  3 
KCNT1 38 0 38 1.00  2 
KCTD1 11 0 11 1.00  1 
KIF5A 15 2 13 0.87  3 
KIT 70 12 58 0.83  6 
KRAS 57 0 57 1.00  12 
KRT16 15 0 15 1.00  2 
KRT17 12 0 12 1.00  2 
KRT6A 17 1 16 0.94  1 
KRT9 12 0 12 1.00  1 
LRRK2 10 2 8 0.80  1 
MAF 17 1 16 0.94  2 
MAP2K1 40 0 40 1.00  1 
MAP2K2 19 0 19 1.00  1 
MAP3K7 10 0 10 1.00  2 
MORC2 10 0 10 1.00  1 
MTOR 26 0 26 1.00  2 
MYL2 14 2 12 0.86  1 
NFE2L2 10 0 10 1.00  1 
NOD2 12 2 10 0.83  3 
NOG 20 4 16 0.80  5 
NOTCH3 119 12 107 0.90  3 
NRAS 29 2 27 0.93  8 
PCSK9 16 2 14 0.88  2 
PDE4D 13 0 13 1.00  1 
PDGFRB 10 0 10 1.00  5 
PIK3R2 11 2 9 0.82  1 
PPP2CA 12 2 10 0.83  1 
PRKAG2 16 0 16 1.00  3 
PRKCG 28 1 27 0.96  1 
PSEN1 67 1 66 0.99  7 
PTPN11 120 12 108 0.90  4 
RAC1 10 1 9 0.90  1 
RAF1 44 0 44 1.00  3 
RBM20 19 3 16 0.84  1 
RET 84 15 69 0.82  7 
RIT1 27 0 27 1.00  1 
RYR2 124 1 123 0.99  2 
SCN8A 113 10 103 0.91  4 
SKI 14 0 14 1.00  1 
SMARCA2 53 1 52 0.98  1 
SMC3 25 2 23 0.92  1 
SNRNP200 13 0 13 1.00  1 
SOS1 48 1 47 0.98  2 
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SPOP 17 0 17 1.00  2 
STAT3 51 1 50 0.98  2 
TBL1XR1 28 5 23 0.82  2 
TGFBR1 34 5 29 0.85  2 
TGFBR2 55 7 48 0.87  3 
TNFRSF1A 18 0 18 1.00  2 
TNNT2 47 4 43 0.91  4 
TPM2 17 3 14 0.82  4 
TRPC6 13 1 12 0.92  1 
TRPV4 55 1 54 0.98  11 
TTR 58 0 58 1.00  3 
TUBA1A 126 1 125 0.99  1 
TUBB 12 0 12 1.00  2 
TUBB2A 15 0 15 1.00  1 
TUBB2B 21 0 21 1.00  1 
TUBB3 26 0 26 1.00  2 
TUBB4A 38 0 38 1.00  2 
UBIAD1 10 0 10 1.00  1 
UMOD 34 1 33 0.97  3 
VCP 16 0 16 1.00  3 










Supplementary table 1.1: Genes likely to cause Mendelian disease predominantly through 
gain-of-function. All genes listed have at least 10 P/LP variants, cause at least one autosomal 
dominant mendelian disorder and have a missense ratio greater than 0.8.  
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Chapter 2: Evidence of shared transcriptomic dysregulation of 
HNRNPU deficiency between 6.5-week-old organoids and 
embryonic, but not perinatal, mice 
 
Introduction 
Despite the enthusiasm often expressed about precision medicine approaches in 
neurodevelopmental disorders (EpiPM 2015), the development of mechanistically targeted 
therapies remains highly challenging.  Indeed, despite remarkable progress in identifying genetic 
causes underlying such disorders (Hu 2014, Tarlungeanu 2018, Parenti 2020), only a handful of 
genetic neurodevelopmental disorders are currently treated with effective, targeted therapies.  
There are likely to be many reasons for this slow progress, but two in particular stand out.  First, 
implicated genes are highly heterogenous, implying the necessity for distinct drug discovery 
paradigms for different genetic disorders.  Second, it is often unclear what model system is most 
suitable for finding and testing targeted treatments.  
 
We systematically explore both of these challenges by focusing on the neurodevelopmental 
disorder caused by HNRNPU deficiency. De novo loss-of-function variants in HNRNPU have 
been found to cause a neurodevelopmental syndrome, with the largest cohort of 21 patients 
exhibiting developmental delay (95%), intellectual disability (52%), craniofacial dysmorphism 
(95%) including microcephaly (20%) and seizures (95%) (Durkin 2020, Yates 2017). HNRNPU 
is expressed throughout development and has been implicated in abnormal cardiac development 
(Ye 2015) and regulates expression of the prominent developmental morphogen Shh (Zhao 
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2009). Further, HNRNPU is an RNA- and DNA- binding protein (Kiledjian 1992, Fackelmayer 
1994, Gohring 1997) found to be involved in diverse processes including alternative splicing 
(Xiao 2012, Ye 2015), chromatin remodeling (Fan 2017) and telomere shortening (Fu 2007). 
 
Recently, Dhindsa et al argued that neurodevelopmental disorder genes, such as HNRPNU, that 
appear to cause disease through widespread dysregulation of the transcriptome or 
epitranscriptome might be treatable through an approach that uses small molecules to move 
genome wide expression patterns back toward the normal state (Dhindsa 2020). Since hundreds 
of genes that function as transcription factors, RNA binding proteins or chromatin remodelers 
(Mossink 2021, Santos-Terra 2021, Zhou 2018, Schieweck 2021) cause neurodevelopmental 
disorders, optimization of such a paradigm might have wide applicability. However, key 
questions about this approach remain unresolved, including identifying appropriate model 
systems capable of characterizing the nature of transcriptomic dysregulation and to test the 
relationship between transcriptomic restoration and functional improvement.  
 
Here, we address these challenges through the characterization of transcriptomic dysregulation in 
an organoid model of HNRNPU deficiency and by comparing differential expression in organoid 
models to mouse models of Hnrnpu deficiency. These comparisons allow us to assess for the first 
time the developmental nature of transcriptomic dysregulation in HNRNPU deficiency and also 
the extent to which patterns of dysregulation in brain organoids are reproducible in an in vivo 
model system. While supporting some aspects of the paradigm outlined by Dhindsa et al., this 






Mouse husbandry and genotyping 
Hnrnpu+/-, Hnrnpufl/- ; Emx1-Cre and Hnrnpufl/fl ; Emx1-Cre mice were generated as previously 
described (Dugger 2020, Sapir 2021). Briefly, Hnrnpu+/- mice were generated via a CRISPR-
induced 113-bp deletion in exon I, while Hnrnpufl/- and Hnrnpufl/fl were generated by specific 
deletion of a genomic DNA region encoding Hnrnpu exons 4-14 (Ye 2015) in Emx1+ cells. For 
genotyping, DNA was extracted from tail or ear clippings and genotypes were determined 
through PCR amplification that generated larger and smaller products for wild-type and mutant 
alleles, respectively. For Hnrnpufl/- and Hnrnpufl/fl mice, Cre expression was independently 
confirmed using PCR amplification. All Hnrnpu+/- mice had access to regular chow and water 
and were maintained within the Columbia University Institute of Comparative Medicine, which 
is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care. Similarly, Hnrnpufl/- and Hnrnpufl/fl mice had access to regular chow and water and were 
maintained within the Weizmann institute as previously described (Sapir 2021).  
 
Human stem cell line generation 
Isogenic mutant lines were generated by SynthegoTM from the publicly available PGP1 founder 
line. CRISPR-Cas9 gene editing was performed using guide RNA sequence 
CCACGGCCATGATCTTCTCG, generating a cut site at Chr: 1; 244,862,672, which is within 
Exon 2 of HNRNPU. Edited clones were expanded and Sanger sequenced, leading to the 
identification of two isogenic mutant lines with +1 bp (‘D11’) and -10bp (‘M20’) indels 
respectively. Both D11 and M20 were assessed by Synthego for pluripotency and normal 
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karyotypes using PluriTest and KaryoStat, respectively. Two vials of 1 million cells were then 
expanded and maintained within Columbia’s Institute for Genomic Medicine (‘IGM’) using 
GeltrexTM-coated plates and mTeSR Plus media. Stem cells were passaged every 3 to 4 days with 
5 mM EDTA. 
 
Human Cortical Organoid Differentiation 
Human Cortical Organoids (‘hCOs’) were generated as previously described (Xiang 2017). 
Briefly, stem cells were dissociated into single cells and 9,000 cells were plated per well of a U-
bottom ultra-low-attachment 96-well plate (Corning, Cat No. CLS7007-24EA) in neural 
induction medium supplemented with 50 µm Rock-inhibitor and 2% FBS. On Day 2, media was 
replaced with 150 µl neural induction medium supplemented with 50 µm Rock-inhibitor. Media 
changes every two days with neural induction media was performed until DIV10, when up to 12 
embryoid bodies were transferred into each well of an ultra-low-attachment 6-well plate and 
placed on a shaker set to 225-250 rpm in 2-3 mls of neural differentiation medium minus 
Vitamin A. Every two days, media was aspirated and 2-3 mls of fresh neural differentiation 
medium minus Vitamin A was added. On day 18, after aspirating wells, neural differentiation 
medium was added. From day 18 through completion of experiments, media was aspirated, and 
fresh neural differentiation medium was added every 4-5 days.   
 
Immunocytochemistry 
On days in vitro 25 and 45, hCOs were washed 2x with 1X PBS in 500 µl EppendorfTM tubes. 
After washing, organoids were fixed for 20-30 minutes in 4% paraformaldehyde at RT. 
Following fixation, organoids were washed 3x with PBS and placed in 4°C cold room overnight 
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in 30% sucrose in PBS. Once all fixed organoids descended to the bottom of Eppendorf tubes, 
they were removed and embedded in Tissue-Tek O.C.T in disposable cryomolds and placed in -
80°C freezer until cryosectioning.  
 
Cryosectioning was done using 20 µm slices and up to three slices were placed onto slides for 
immunocytochemistry. Slides were either returned to the -80°C freezer for future staining or air 
dried for 30 minutes at RT. Following air-drying, fixed slices were washed 2x with PBS and then 
incubated in blocking solution (5% donkey serum and 0.3% Triton X-100 in PBS) for 1-2 hours 
at RT. After blocking, slides were placed in humidified chambers overnight at 4°C in blocking 
solution supplemented with primary antibodies. The next morning, slides were washed 3X with 
PBS and then incubated in blocking solution supplemented with Alexa Fluorophore conjugated 
secondary antibodies for 1-2 hours in the dark at RT. Finally, slides were rinsed 4X with PBS 
and covered by coverslips with ProLongTM Diamond Antifade Mountant with DAPI. After at 
least 24 hrs of drying in the dark, Imaging was performed using the Zeiss Axio Observer.Z1 
Fluorescence Motorized Microscope and associated Zen2 Pro imaging software. Downstream 
image processing was performed using PowerPoint, using consistent adjustments to brightness 
and/or contrast across like images.  
 
Western blotting 
Stem cells were placed on ice and rinsed 3X with ice cold PBS. Cells were homogenized using a 
cell scraper in cold RIPA buffer containing protease and phosphatase inhibitors (Roche). Lysis 
was completed for 15 minutes on ice and samples were centrifuged at >8000 RPM for 30 
minutes at 4°C. The resulting supernatant was collected, and protein quantified using BCA 
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method with BSA-based standards. Protein lysates were diluted in LDS sample buffer and 
Laemmli buffer. Samples were boiled at 95°C and 5µg was loaded onto a 4-12% Bis-Tris gel in 
SDS running buffer supplemented with NuPAGE antioxidant and run at 150V for 45 minutes. 
Protein was then transferred using the Xcell II Blot Module to 0.2 um methanol-activated PVDF 
membrane at 30 V for 1.5 hrs at 4°C in Transfer buffer containing 20% methanol. Membranes 
were then blocked for 1 hour in 5% milk at RT and incubated overnight in HNRNPU primary 
antibody at 1:1000 dilution (Rabbit monoclonal against N-terminus: Abcam ab180952). Blots 
were developed using Amersham ECL reagents (RPN2105) and imaged with an Azure 300 
system. For a loading control, blots were subsequently incubated in an HRP-conjugated b-Actin 
secondary at 1:1000 (Santa Cruz #sc-47778) diluted in 5% BSA for 1 hr at RT. Protein 
expression was quantified using ImageStudioLite with normalization to b-Actin. 
 
RT-qPCR 
RNA was extracted from stem cells using RNeasy Plus Mini Kit (QIAGEN) and cDNA was 
generated using SuperScript IV (ThermoFisher) with random hexamers. cDNA was then diluted 
to approximately 2.5 μg / μl based off quantification of initial RNA concentration using a 
NanoDrop (ThermoFisher). In each well of a 384-well plate, 10 μg of cDNA (4 μl) was added 
alongside 5 μl of TaqMan Fast Universal PCR Master Mix 2X and 0.5 μl each of a FAM-
conjugated HNRNPU TaqMan probe and a VIC-conjugated GAPDH probe for an internal 
control. PCR amplification and quantification of fluorescence was done using a QuantStudioTM 5 
Real-Time PCR System. Comparative CT analysis was used and mean and error bars generated 






Bulk RNA-sequencing for Hnrnpufl/- and Hnrnpufl/fl cortices was generated as previously 
described (Sapir 2021). Similarly, all other bulk RNA-sequencing samples were generated by 
manual dissection of cortices from either embryonic (E13) or perinatal mice (P0 or P1) and flash 
freezing dissociated cortices or incubating in RNAlater prior to RNA extraction. Once mice were 
genotyped, RNA was generated from relevant cortices using the RNeasy Plus Mini Kit 
(QIAGEN). To ensure quality of RNA, purity was confirmed using a Bioanalyzer (Instrument 
Name DE72901373, Firmware C.01.069, Type G2939A). Samples with a RIN score >9 were 
sent for RNA sequencing. Poly-A pull-down was used to enrich mRNAs from total RNA 
samples and libraries were constructed using Illumina TruSeq chemistry. Libraries were then 
sequenced using Illumina NovaSeq 6000 at Columbia Genome Center. RTA (Illumina) was used 
for base calling and bcl12fastq2 (version 2.19) was used to convert BCL to fastq format, coupled 
with adaptor trimming. Pseudoalignment was performed to a kallisto index (Mouse: GRCm38) 
using kallisto (0.44.0).  
 
Differential expression analysis was performed with DESeq2. Differentially expressed genes 
were identified using DESeq2’s likelihood ratio test (‘LRT’). When genders and litters of mice 
were distributed across conditions, they were used as latent variables. Genes were considered 
differentially expressed using FDR < 0.05 and no threshold for fold change. For samples with 
fewer than ten FDR < 0.05 DEGs, unadjusted p-values < 0.05 were used to determine DEGs for 






hCOs were dissociated into single cells using Papain in EBSS supplemented with DNAse at 
DIV45-47. Briefly, 6 (experiment 1) or 12 (experiment 2) hCOs per genotype were aggregated 
together into a 1 ml EppendorfTM tube and rinsed 2X with PBS then incubated in Papain solution 
for 30-45 minutes at 37°C with agitation every 10-15 minutes. A 1000 µl pipet was then used to 
triturate organoids into single cells. Cells were then spun down at 0.4 xg for 5 minutes. Cells 
were resuspended in PBS with 5% FBS and viability was calculated using Trypan Blue and 
manual counting on a hemocytometer. Populations with >90% viable cells were placed on ice 
and brought to JP Sulzberger Columbia Genome Center for sample preparation and single-cell 
RNA-sequencing.  
 
Single-cell RNA-sequencing data analysis 
We used Seurat v3 (Stuart 2019) to perform downstream QC and analyses on feature-barcode 
matrices. First, we removed all genes that were not present in at least 3 cells and removed all 
cells that did not express at least 200 genes. We then removed all cells with greater than 7500 
genes expressed or greater than 10% mitochondrial reads to remove potential doublets and low-
quality cells. The filtered matrices were log-normalized and scaled to 10,000 transcripts per cell. 
We used variance-stabilization transformation to identify the 2,000 most variable genes. We used 
Seurat’s data integration matrix to synchronize all 15 samples using reciprocal PCA across 3 
experiments and 3 lines using 30 dimensions and latent variables Mitochondrial DNA percentage 
and reads per cell. Following integration of data, we identified clusters using Seurat’s 
FindNeighbors (dimensions = 11) and FindClusters functions (resolution = 0.5). We used UMAP 
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reduction and Seurat’s DotPlot and VlnPlot functions to visualize clusters and cell-type specific 
expression of genes.  
 
To annotate clusters, we used Seurat’s FindConservedMarkers function, which implements a 
Wilcoxon test and used Bonferroni correction to identify genes enriched in certain clusters. We 
only considered genes with positive enrichment and expressed in at least 5% of cells. Annotation 
of clusters was done through a combination of expression of canonical markers visualized with 
DotPlot function and GO ontologies of most enriched genes (supplementary figure 2.6).  
 
To identify differentially expressed genes, we used Seurat’s FindMarkers function using MAST 
with a log fold change threshold of 0.25 and only considered genes expressed in at least 5% of 
cells. Mitochondrial percentage and read count were used as latent variables. For Pseudobulk 
analyses, all cells were considered, while cell-type specific analyses were done by subsetting 
population prior to MAST analysis. A Similar approach was used to identify all Pseudobulk and 
cell-type specific differentially expressed genes with minimal adjustments. When considering 
samples from experiment 1 and experiment 2 together, batch was additionally used as a latent 
variable. For burden analyses, each cluster for each sample was randomly downsampled to 47 
cells (n = 235 total cells per line), the minimum number of cells in any of the clusters considered 
for a given sample. To ensure phenotype was robust to sampling bias, we downsampled and 
identified differentially expressed genes 10 times and averaged the number of differentially 
expressed genes across the 10 iterations. Genes were considered differentially expressed with a 




Comparison of transcriptomic dysregulation across samples 
Pseudobulk analysis of all 5 samples of D11 and M20 combined was compared to PGP1 in 
cross-species comparisons. Two basic analyses were performed when comparing dysregulation 
across species, models or developmental time points. First, the log2 fold change of all DEGs for 
HNRNPU+/- hCOs were plotted on the x-axis, while the log2 fold change of their species-
correlate were plotted on y-axis and a best-fit linear regression line with slope and R2 coefficient 
were calculated and displayed. We then show how correlation coefficient is altered when 
considering only genes that pass certain thresholds of significance in the dataset displayed on y-
axis. For all other graphs comparing log2fc between models or time points, plots and linear 
regression lines are generated similarly with only genes significant dysregulated in both data sets 
being considered. Secondly, we calculate the geometric mean enrichment (‘GME’) of all 
combinations of upregulated and downregulated genes to quantify whether or not upregulated or 
downregulated genes are significantly enriched across species, model and time point. Here, we 
use a one-sided Fisher test on a 2*2 matrix to calculate GME and associated p-value. For 
example, when considering genes upregulated across data sets, the 2*2 matrix includes genes 
upregulated in both datasets and genes upregulated in dataset 1 alone in the first row. The second 
row of input matrix includes genes upregulated in dataset 2 alone followed by all genes not 
upregulated in dataset 2. Importantly, the number of total genes considered for enrichment 
analyses is determined by number of genes considered for differential expression testing in both 
data sets (genes with total reads > 10 for bulk-RNA samples and present in 5% of D11/M20 or 
PGP1 cells for pseudobulk across both experiments were considered). GME fold enrichment and 
associated p-value were generated for all combinations of up and downregulated genes. 
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Importantly, for models with fewer than 10 FDR adjusted DEGs, unadjusted p-value of .05 is 
used for all the analyses described above.  
 
Size Quantification of hCOs 
Phase contrast images of hCOs were taken at DIVs 10 and 45 on an Echo Revolve microscope 
with 2X magnification. Using the revolve software on an iPad, the borders of hCOs were drawn 
with an accompanying stylus and area was quantified. 
 
Gene Ontologies 
Gene ontology analysis was performed using ShinyGO software 
(http://bioinformatics.sdstate.edu/go/ , Ge 2020). Genes upregulated and downregulated in same 
direction in both D11 and M20 hCOs were queried for enrichment of biological processes and 
molecular function. All upregulated and downregulated genes considered for gene ontology 
analyses are in supplementary table 2.1.  
Neural induction medium 
• DMEM/F-12 (Caisson Labs, Cat No. DFL15) 
• Knockout serum replacement (Thermo Fisher, Cat No. 10828-028) 15% (v/v) 
• MEM-NEAA (Thermo Fisher, Cat No. 11140050) 1% (v/v) 
• Glutamax supplement (Thermo Fisher, Cat No. 35050061) 1% (v/v) 
• β-Mercaptoethanol (Sigma, Cat No. M7522) 100 μM 
• LDN-193189 (Sigma, Cat No. SML0559) 100 nM 
• SB431542 (Reprocell, Cat No. 04001005) 10 μM 
• XAV939 (Stemgent, Cat No. 040046) 2 μM 
Neural differentiation medium minus vitamin A 
• DMEM/F-12 (Caisson Labs, Cat No. DFL15) 
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• Neurobasal medium (Thermo Fisher, Cat No. 12348017) 
• Insulin (Santa Cruz, Cat No. sc-360248) 0.025% (v/v) 
• MEM-NEAA (Thermo Fisher, Cat No. 11140050) 1% (v/v) 
• Glutamax supplement (Thermo Fisher, Cat No. 35050061) 1% (v/v) 
• Penicillin/Streptomycin (Caisson Labs, Cat No. PSL01) 1% (v/v) 
• N2 supplement (Thermo Fisher, Cat No. 17502048) 0.5% (v/v) 
• B27 supplement without vitamin A (Thermo Fisher, Cat No. 12587010) 1% (v/v) 
• β-Mercaptoethanol (Sigma, Cat No. M7522) 50 μM 
Neural differentiation medium 
• DMEM/F-12 (Caisson Labs, Cat No. DFL15) 
• Neurobasal medium (Thermo Fisher, Cat No. 12348017) 
• Insulin (Santa Cruz, Cat No. sc-360248) 0.025% (v/v) 
• MEM-NEAA (Thermo Fisher, Cat No. 11140050) 1% (v/v) 
• Glutamax supplement (Thermo Fisher, Cat No. 35050061) 1% (v/v) 
• Penicillin/Streptomycin (Caisson Labs, Cat No. PSL01) 1% (v/v) 
• N2 supplement (Thermo Fisher, Cat No. 17502048) 0.5% (v/v) 
• B27 supplement without vitamin A (Thermo Fisher, Cat No. 12587010) 1% (v/v) 
• β-Mercaptoethanol (Sigma, Cat No. M7522) 50 μM 
• BDNF (R&D Systems, Cat No. 248-BDB-050) 20 ng/ml 
• Ascorbic acid (Tocris, Cat No. 4055) 200 μM 
Results 
Generation of HNRNPU+/- stem cell lines 
In order to characterize transcriptomic dysregulation in a human model of HNRNPU deficiency, 
we first generated two isogenic mutant lines using the publicly available PGP1 stem cell line 
(RRID:CVCL_F182) with a 1 bp duplication (‘D11’) and a 10 bp deletion (‘M20’), respectively 
(figure 2.1). Mutations in D11 and M20 result in a frame-shift and a premature stop-codon in 
exons 2 and 4 respectively (supplementary figure 2.1). Importantly, both D11 and M20 stem 
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cells exhibited a significant reduction in HNRNPU mRNA expression, alongside an ~25% 
reduction in protein levels (figure 2.1).  
 
HNRNPU+/- cortical organoids show consistent transcriptomic dysregulation and size 
difference versus isogenic controls 
We next generated human HNRNPU+/- cortical organoids (‘hCOs’) as described previously 
(Xiang 2017) and similarly identified VZ-like regions in 25-day-old hCOs generated from PGP1, 
D11 and M20 hiPSCs (figure 2.1). By day 45, hCOs widely expressed BIII-tubulin, a neuronal 
marker, and additionally included GABAergic subpopulations (figure 2.1). While all stem cell 
lines were capable of generating hCOs, both HNRNPU+/- mutant lines generated significantly 
smaller organoids, with a size phenotype emerging as early as DIV 10 and maintaining 
throughout the ~6.5-week long experiment (figure 2.1). The reduction in size of hCOs may 
phenocopy the subset of human patients with microcephaly. Further, size phenotypes have been 
identified in distinct mouse models of HNRNPU deficiency. An Hnrnpu heterozygous knockout 
mouse model with a constitutive 113 base pair deletion in exon 1 results in a significant size 
reduction in mice, with proportional cortical thickness (Dugger 2020). Similarly, a distinct 
constitutive heterozygous mutation that generates a truncated protein shows a similar overall size 
reduction in mutant mice (Ebstein 2017). Finally, the same truncating mutation, specifically 
disrupted in Emx1+ cells, results in significant reduction in cortical size in homozygous mice 
(Sapir 2021). 
 
Once we confirmed HNRNPU+/- hCOs successfully differentiated into appropriate neuronal 
populations and displayed a size difference consistent with a subset of patient and mouse model 
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phenotypes, we aimed to identify a robust signature of transcriptomic dysregulation in mutant 
hCOs. After 45 days in vitro, cortical organoids were dissociated into single cells and sequenced. 
To help ensure the transcriptomic signature was robust, we sequenced a total of 42 organoids per 
line, with five biological replicates from three experiments in two batches of single-cell RNA 
(‘scRNA’) sequencing. Using pseudobulk analyses from scRNA-seq samples, we found 
significant overlap of both upregulated and downregulated genes across batches and across 
mutant cell lines, with higher replication of DEGs between batches (supplementary figure 2.2).  
 
HNRNPU+/- organoids show disruption in neurodevelopmental processes and ribosomal 
proteins 
We then further characterized the patterns of dysregulation seen in HNRNPU+/-  hCOs at both 
pseudobulk and cell-type specific resolution. When characterizing transcriptomic dysregulation, 
we chose to prioritize specificity over sensitivity of dysregulated genes and determined genes to 
be differentially expressed if they were significantly enriched in both D11 and M20 organoids 
(log2fc > .25, FDR<.05). Using this relatively stringent approach, we identified 281 
downregulated and 475 upregulated genes. Importantly, downregulated genes were most heavily 
enriched for ribosomal proteins and genes associated with molecular functions including nucleic 
acid binding and RNA binding, both reported as prominent functions of HNRNPU (Kiledjian 
1992, Kim 1999, Nozawa 2017). Similarly, upregulated genes were heavily enriched for 
neurogenic and neurodevelopmental processes (figure 2.2a) with several genes implicated in 
neurodevelopmental disorders present in the top 18 upregulated DEGs (log2fc>1) including 
NR2F1 (Bosch 2014), SYT1 (Baker 2018) and GAD1 (Chatron 2020). Thus, patterns of 
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dysregulation in an organoid model of HNRNPU deficiency are directionally consistent with an 
RNA-binding protein driven neurodevelopmental disorder.  
 
HNRNPU+/- hCOs show compositional differences and differential burden of DEGs 
between precursor populations and neurons 
Even within several weeks in vitro, hCOs include a heterogeneous population of cortical cell 
types (Xiang 2017). Further, Dugger et al., recently identified increased burden of dysregulation 
in a specific subpopulation of cells in a mouse model of Hnrnpu haploinsufficiency (Dugger 
2020). Thus, we aimed to further characterize transcriptomic dysregulation in an organoid model 
at single-cell resolution. We first used the Seurat pipeline (Stuart 2019) to synchronize all 
samples into a single shared space and annotated clusters using a combination of canonical 
markers and GO ontologies (Ashburner 2000, The Gene Ontology Resource 2021).  
 
Briefly, we first identified neuronal populations by expression of DCX, STMN2 and GAP43. 
Within the neuronal populations, one cluster did not show enrichment of GABAergic markers or 
excitatory neuronal markers and was labeled as non-committed neuron. Remaining clusters were 
considered GABAergic (GAD1, GAD2), cortical projection neurons (NEUROD2, NEUROD6), 
SCPNs (FOXP2, NTNG2, RORB) or neuron (GO: Glutamate secretion).  
 
Neural clusters without significant populations of neurons (VIM, NES, HES1) were annotated as 
NSCs, NPCs, intermediate progenitors, high-metabolism intermediate progenitors (‘HMIs’), glial 
progenitors and OPCs using GO ontologies for upregulated genes in specific clusters 
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(supplementary figure 2.3). D11, M20 and PGP1 organoids generated cells from all 11 
populations (figure 2.2b). 
 
We then investigated whether or not both mutant cell lines, D11 and M20, showed consistent 
disruption in generating certain cell populations (figure 2.2c, supplementary table 2.2). Here, the 
5 organoid samples for each line were considered as independent replicates and we assessed 
compositional differences for each mutant line to ensure aberrant population proportions were 
robust. We found consistent reduction in NPCs and HMIs in both mutant clones. Similarly, 
GABAergic and SCPN populations were enriched in one mutant line with corresponding 
borderline significance (p<.06) in the second mutant clone. Importantly, reduced populations 
were evident in progenitor and intermediate populations, whereas enriched populations were in 
committed neuronal populations.  
 
Finally, we considered whether or not certain cell populations were more heavily burdened in 
D11 and M20 organoids. We first identified similar expression of HNRNPU across all neuronal 
subtypes (supplementary figure 2.4). We restricted our analyses to clusters with greater than 10 
cells in all 15 samples, which led to the exclusion of HMI, SCPN and OPC populations. All 
remaining clusters had at least 47 cells in every cluster. Thus, we downsampled each cluster in 
every sample to 47 cells to ensure burden analyses were not driven by sample bias. For both D11 
and M20, precursor populations (NSCs, glial progenitors, NPCs and intermediate progenitors) 
tended to be more heavily burdened than neuronal populations (noncommitted, cortical, 
GABAergic and neuron). Interestingly, both compositional analyses and burden analysis are in 
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line with findings in Hnrnpufl/fl mice showing instability and death in excitatory neuronal 
progenitor populations (Sapir 2021).  
 
Thus, HNRNPU+/- hCOs show a characteristic pattern of dysregulation shared across isogenic 
mutant lines, including evidence of cell-type specific burden of dysregulated genes, with more 
immature cell types exhibiting increased burden of disease. For either global or cell-type specific 
dysregulation of HNRNPU+/- hCOs to be suitable for potential therapeutic reversal, such 
dysregulation must be scalable to an in vivo system. Since characterizing transcriptomic 
dysregulation in the brains of patients is intractable, we instead consider whether or not 
transcriptomic dysregulation in a human model is partially reproduced in vivo using mouse 
models of Hnrnpu deficiency. 
 
Transcriptomic dysregulation of HNRNPU+/- cortical organoids replicated in E13 cortices 
While attempts at broad transcriptomic or epitranscriptomic comparisons of a human and mouse 
model of neurodevelopmental disease are exceedingly rare, the few existing studies suggest 
consideration of developmental time point may be necessary to identify concordant 
dysregulation across model systems (supplementary figure 2.5). Recent pseudotime analyses of 
hCOs generated similarly to those described herein suggest that around 6.5-week-old hCOs 
correspond closest to fetal human brains around post-conception week (‘pcw’) 10 (Tanaka 
2020). Further, a recent single-cell transcriptomic analysis of mouse neocortex found that E14.5 
mouse cortices most closely resemble humans between 7 to 11.5 pcw, while P0 mice are most 
analogous to pcw 20-23 in fetal samples (Loo 2019). Thus, we first compared the dysregulation 




We initially considered two distinct mouse models for investigation, a constitutive knockout 
(Dugger 2020) and a conditional truncating mutation in neocortical excitatory neurons (Emx1-
Cre+) and glia. Bulk-RNA sequencing for E13 heterozygous “Hnrnpufl/-” and homozygous 
“Hnrnpufl/fl” cortices has previously been analyzed (Sapir 2021), while constitutive “Hnrnpu+/-” 
embryonic cortices were dissected and sequenced. Importantly, while initial characterization of 
hCOs express populations of GABAergic neurons at 72 and 79 days in vitro, such organoids 
were found to recapitulate dorsal cortical development (Xiang 2017), suggesting hCOs may be 
enriched for excitatory neuronal processes. Thus, we did not have initial assumptions as to which 
model may better recapitulate transcriptomic dysregulation seen in cortical organoids.  
 
When using a simple threshold of FDR-adjusted p-values <.05 following differential expression 
analysis with DESeq2, we identified a large number of DEGs (n = 2,802) for Hnrnpufl/- 
embryonic mice and relatively few for time matched Hnrnpu+/- cortices (n = 172). Further, 
Hnrnpufl/- samples clearly coclustered in PC space, while Hnrnpu+/- samples were not 
distinguishable from WT litter mates and segregated instead by gender (supplementary figure 
2.6). We thus prioritized the Hnrnpufl/- for cross-species comparisons given the stronger evidence 
of widespread dysregulation and a larger number of DEGs to assess. 
 
For cross-species comparisons, we considered all differentially expressed genes (‘DEGs’) 
identified in hCOs across 5 samples per line, with D11 and M20 treated as biological replicates 
for HNRNPU deficiency. Thus, a single log fold change value for each gene differentially 
expressed in HNRNPU+/- hCOs can be generated. To assess whether or not transcriptomic 
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dysregulation in a human in vitro system is reproduced in vivo, we first plotted the log fold 
change of all hCO pseudobulk DEGs versus the log fold change of their mouse correlates in bulk 
E13 RNA sequencing of Hnrnpufl/- cortices and wild-type litter mates. Interestingly, even 
without any log fold change or significance thresholds for E13 mice, there is evidence of 
recapitulation of hCO signature, with a modest R2 of 0.13. With increasingly stringent FDR-
adjusted p-value thresholds, the correlation increases up to an R2 of 0.29 (figure 2.3b). 
Importantly, such correlation is seen across species, mutations and subtype specificity, with 
selective reduction of Hnrnpu in Emx1+ cells, suggesting such cross-species comparisons can be 
robust. 
 
Once we identified positive correlation of the transcriptomic signature seen in hCOs, we 
quantified the overlap of FDR-adjusted DEGs between HNRNPU+/- hCOs (n=1,183, 796 
upregulated, 387 downregulated) and Hnrnpufl/- cortices (n=2,802, 1,519 upregulated, 1,283 
downregulated). We found highly significant enrichment in genes both similarly upregulated and 
similarly downregulated, without any enrichment of genes dysregulated in opposing directions 
(figure 2.3c,d ; supplementary table 2.3). Reassuringly, we identify more modest, but consistent 
patterns between hCOs and Hnrnpu+/- embryonic cortices, with an R2 coefficient of 0.31 for 
log2fc of DEGs and 6.2-fold enrichment of downregulated genes without any corresponding 
enrichment of discordant gene sets (supplementary figure 2.7a).  
 
Transcriptomic dysregulation of perinatal mice discordant with HNRNPU+/- cortical 
organoids and E13 mice 
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Paradigms of transcriptomic reversal rely on patterns of dysregulation to be recapitulated in 
pediatric patients and transcriptomic dysregulation may not necessarily be static throughout 
development. Given the extended timelines of human neurodevelopment compared to mice 
(Semple 2013) and the partial reproduction of HNRNPU+/- disease signature in embryonic mice, 
we examine a perinatal murine time point to address whether or not transcriptomic signatures of 
HNRNPU deficiency may be stable. We first asked whether or not the transcriptomic 
dysregulation seen in embryonic mice was reproduced perinatally. To this end, we considered 
the dysregulation of both Hnrnpufl/- and Hnrnpufl/fl mice at an embryonic and perinatal time 
point. Interestingly, while both heterozygous and homozygous genotypes cleanly clustered 
together at embryonic time points, perinatal heterozygous samples predominantly co-clustered 
with matched wild type samples (figure 2.4a), suggesting more limited disruption later in 
development. 
 
We then examined whether or not significantly dysregulated genes at perinatal time points were 
consistent with embryonic mice. Due to the limited overall disruption in heterozygous mice, 
unadjusted p-values were used to determine significant genes in those samples, while FDR-
adjusted p-values were considered for homozygotes. Surprisingly, the most significant finding 
for both mouse models was enrichment of discordant gene sets (figure 2.4b). 
 
We similarly assessed whether dysregulation of HNRNPU+/- hCOs was similarly discordant with 
perinatal mice. We found genes downregulated in HNRNPU+/- hCOs were significantly 
upregulated in Hnrnpufl/- mice. Similarly, while HNRNPU+/- hCOs and Hnrnpufl/fl mice showed 
enrichment of co-upregulated and co-downregulated genes at an embryonic time point, the 
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strongest enrichment at a perinatal time point was once again upregulation of genes 
downregulated in hCOs. Further, when considering the log fold change of DEGs in organoids 
versus DEGs in perinatal Hnrnpufl/- and Hnrnpufl/fl samples, we found evidence of modest 
transcript level anti-correlation (R2 of .19 and .10 respectively, supplementary figure 2.7).  
 
Finally, we examined perinatal Hnrnpu+/- P0 cortices to see whether the same directional effects 
were present and similarly found modest anticorrelation (R2 of .15, supplementary figure 2.8b). 
While there was no evidence of concordant or discordant gene sets, we examined whether or not 
the genes discordant between hCOs and perinatal Hnrnpufl/- cortices may be recapitulated, but 
underpowered. Significantly, 27 of the 31 discordant genes showed raw increases in log fold 
change, suggesting such genes are similarly upregulated in newborn Hnrnpu+/- mice 
(supplementary figure 2.8c). Interestingly, discordant genes are enriched for ribosomal proteins, 
in addition to including genes such as Cdkn1a and Eif3m, which have been found to be involved 
in cell-cycle arrest (Dutto 2015) and organ size (Zeng 2013), respectively. 
 
In summary, HNRNPU+/- hCOs reproduce significant aspects of transcriptomic disruption in 
embryonic mice but are strikingly discordant with perinatal samples. Importantly, compositional 
differences may underlie a portion of the discordance of dysregulated genes between perinatal 
cortices and hCOs and embryonic samples. Several glial populations emerge from Emx1-
expressing precursors (Gorski 2002) and gliogenesis emerges around E16.5 (Zhang X. 2020). 
Glial populations may have distinct patterns of dysregulation driven by Hnrnpu deficiency and 





Within this work we aimed to address whether or not human organoid systems can be utilized in 
therapeutic stratagems to characterize and reverse transcriptomic dysregulation driven by the 
large number of genes that may cause neurodevelopmental disorders through widespread 
dysregulation of the transcriptome. We begin to explore this fundamental question by first 
characterizing dysregulation in a human cortical organoid model of HNRNPU deficiency. We 
first identified modest reduction (~25%) in HNRNPU expression consistent with a previously 
described constitutive mouse model. Further, HNRNPU deficiency in hCOs resulted in a 
significant size reduction, consistent with both evidence of microcephaly in a subset of patients 
and size reduction across several mouse models of Hnrnpu deficiency. After identifying 
recapitulation of basic features of HNRNPU deficiency in a human model, we examined 
transcriptional dysregulation at global and cell-type specific resolutions. 
 
Importantly, human brain organoid systems are known to suffer from high levels of variability, 
amongst other concerns about how faithfully brain organoid systems recapitulate aspects of the 
fetal brain (Tian 2020). In order to account for inter-organoid and experimental batch variability, 
we utilized a total of 42 organoids across three different experiments and two different 
sequencing for two isogenic HNRNPU+/- stem cell lines for transcriptomic analyses. Promisingly, 
we were able to identify strong consistency of DEGs in 6.5-week-old HNRNPU+/- hCOs across 
independent differentiations and distinct isogenic mutant lines (supplementary figure 2.2). When 
considering only genes differentially expressed in both isogenic lines, we identified widespread 
dysregulation of the transcriptome with downregulated genes enriched for gene ontologies 
consistent with the known functions of HNRNPU (nucleic acid binding, RNA binding). Further, 
71 
 
upregulated genes were enriched for neurodevelopmental processes and several genes implicated 
in neurodevelopmental disorders were amongst the most upregulated.  
 
A significant outstanding question in transcriptomic reversal therapeutic paradigms is whether to 
consider cell-type specific or more global transcriptomic dysregulation. Thus, we further 
characterized HNRNPU deficiency in hCOs at single-cell resolution. First, we performed 
compositional analyses and identified significant reductions in progenitor populations, (hmi and 
npc) alongside corresponding increases in certain more mature neuronal populations 
(GABAergic and scpn). We then identified a trend of increased burden in precursor populations 
versus more mature neurons, suggesting transcriptomic signatures may be sensitive to cell-type. 
Importantly, we only considered a singular developmental time point. While 6.5-week-old 
organoids are heterogeneous, the neuronal populations remain highly immature. A recent report 
suggests human brain organoids are capable of generating cell types more similar to postnatal 
populations, but maturation timelines of at least 250-300 days are required (Gordon 2021). 
Characterizing transcriptomic dysregulation in significantly older organoids would be necessary 
to properly characterize the presence or absence of cell-type specific dysregulation in a human 
system. 
 
While HNRNPU+/- hCOs show evidence of widespread transcriptomic dysregulation, whether or 
not an in vitro system is scalable to in vivo disease is critically unclear. Species-specific 
transcriptomic differences are likely to exist between humans and mice for all transcriptional 
regulators involved in neurodevelopmental disorders, including HNRNPU, given highly distinct 
developmental timelines and brain complexity. However, in certain instances, significant 
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elements of dysregulation may be conserved and mouse models and be used to validate human in 
vitro systems are scalable to an in vivo system. Within this work, we show transcriptome level 
dysregulation in a human organoid system is not predominantly driven by in vitro artifacts, as 
disease signature shows enrichment of co-dysregulated genes with embryonic mouse models.  
 
Critically, the transcriptomic signature of HNRNPU deficiency in 6.5-week-old human 
organoids is not reproduced in mice at perinatal time points. Such divergent dysregulation is 
consistent with assessing the developmental trajectory of differential expression exclusively in 
mouse systems. In fact, in both Hnrnpufl/- and Hnrnpufl/fl mice, the most significantly enriched 
gene sets are genes with opposing direction. Thus, transcriptomic signatures of HNRNPU 
deficiency are highly confounded by developmental time point and considering the maturity of 
model system is absolutely essential when developing therapeutics for patients.  
 
Importantly, as the brain develops, cell type composition is variable, with certain populations of 
cells, such as glia, emerging later in neurodevelopment. Performing single-cell sequencing at 
several developmental time points would allow for a more robust assessment of whether 
transcriptomic differences are specific to cellular ages and/or subtypes.   
 
In total, we have shown an immature organoid model of HNRNPU deficiency has dysregulation 
consistent with embryonic time points, but not perinatal time points. Further, even though we 
only considered a single time point, we were able to identify preliminary evidence of 
developmental differences in transcriptional signature in a human model, with precursor 
populations exhibiting increased burden of dysregulated genes compared to more mature 
73 
 
neuronal populations. However, to robustly investigate both developmental and cell-type 
specificity of dysregulation in a human model of HNRNPU deficiency, a time course of single-
cell RNA sequencing with organoids up to hundreds of days old may be required. Mouse models 
of Hnrnpu deficiency may also be confounded by cell-type specificity and single-cell sequencing 
across time points may elucidate whether certain cell populations, including both neuronal and 
glial subtypes, have patterns of dysregulation that are more stable over certain developmental 
time windows.  Such analyses in mouse and human systems could be used to determine if and 
when the transcriptomic signature of HNRNPU deficiency may begin to stabilize. 
 
HNRNPU is just one of hundreds of genes that may cause a neurodevelopmental disorder 
through widespread perturbation of the transcriptome and alternative genetic disorders may have 
more stable transcriptomic signatures. Nevertheless, this work underscores concerning 
limitations of therapeutic paradigms relying on transcriptional reversal. Specifically, 
inappropriate therapeutic reversal of gene expression based on dysregulation in immature human 
organoids may actually exacerbate patient phenotypes in instances where disease signature is 














Figure 2.1: HNRNPU+/- stem cell lines successfully differentiate into human cortical 
organoids with significant size reduction. a) Two isogenic HNRNPU+/- mutant stem cell lines 
were generated by SynthegoTM and representative phase contrast images of stem cell 
populations are shown.  b) Both HNRNPU+/- stem cell lines show approximately 25% 
reduction in HNRNPU mRNA (left) and protein (right) expression compared to internal 
controls. * = p<.05. NS = not statistically significant. c) HNRNPU+/- hCOs show significant 
size reduction emerging by DIV10 and continuing through 45 days in vitro. * = p<.05. d) 
D11, M20 and PGP1 exhibit VZ-like proliferative zones at DIV25 (left) and widespread 










Figure 2.2: HNRNPU+/- hCOs show disruption in ribosomal proteins and neurodevelopmental 
processes. a) Upregulated genes in HNRNPU+/- hCOs enriched for neurodevelopmental 
ontologies, including neurogenesis, morphogenesis and differentiation. b) Downregulated 
genes enriched for functional annotations including DNA-binding and RNA-binding. c) 
UMAP visualization of annotated clusters across all five samples for D11, M20 and PGP1. 
‘npc’ = neuronal progenitor. ‘nsc’ = neural stem cell. ‘hmi’ = high metabolic intermediate 
progenitor. ‘scpn’ = sub-cortical projection neuron. ’opc’ = oligodendrocyte precursor. d) 
Compositional analysis shows significant reduction (* = p<.05) in NPC and HMI populations 
for both D11 and M20 hCOs. Significant or trending significant (* = p<.06) increases in 
SCPN and GABAergic populations for both D11 and M20 hCOs. e) and f) show burden of 
dysregulated genes increased in precursor populations versus more mature neuronal 
population. Number of DEGs generated using 47 cells per cluster per sample to control for 
cell number and sample bias. FDR-correct p-values and a log2 fold change threshold of 0.25 
were used. Final DEGs averaged across 10 simulations to minimize impact of selection bias. 












Figure 2.3: Consistent dysregulation between DIV45 HNRNPU+/- hCOs and E13 Hnrnpufl/- 
mouse cortices. a) Overview of differentially expressed genes (DEGs) in E13 cortices and 
hCOs. b) Log2 fold change of all hCO DEGs were plotted against  log2 fold change values of 
correlate genes in E13 Hnrnpufl/- mouse cortices, without consideration of whether or not 
those changes were identified as differentially expressed in E13 samples (left). A best fit 
linear regression line was plotted and resulted in an R2 coefficient of 0.13. Same analysis was 
performed considering only genes that were both differentially expressed in hCOs and FDR 
adjusted significance thresholds in mice of either p<0.5 (middle) or p<0.05 (right). When 
considering genes with FDR<0.05 in both models, R2 coefficient increases to 0.29. 
Quanitification of geometric mean enrichment further shows significant enrichment of both 











Figure 2.4: Transcriptomic signature of HNRNPU deficiency diverges in perinatal mice. a) 
Evidence of reduced transcriptomic dysregulation in perinatal Hnrnpufl/- cortices. Both 
heterozygous and homozygous mice segregate in PC space in RNA-sequencing of embryonic 
cortices, but heterozygous samples do not segregate at a perinatal time point. “F” = female. 
“M” = male. b) Both Hnrnpufl/- and Hnrnpufl/fl cortices show most significant geometric mean 
enrichment is in genes differentially expressed in opposing directions at embryonic and 
perinatal time points. c) Downregulated genes in DIV45 HNRNPU+/- hCOs are significantly 
enriched in gene sets that were identified as upregulated in both Hnrnpufl/- and Hnrnpufl/fl P1 
cortices.  
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Supplementary table 2.1: Upregulated and downregulated 
genes in HNRNPU+/- hCOs. Pseudobulk analyses with MAST 
were used for both D11 and M20 and genes differentially 
expressed in same direction (FDR<.05, log2 fold change >0.25) 
were considered differentially expressed.  





















Supplementary figure 2.1: Generation of HNRNPU+/- knockout stem cell lines. Both D11 
and M20 cell lines were generated using CRISPR-Cas9 and cut location Chr: 1; 244,862,672, 
which is within Exon 2 of HNRNPU. a) D11 has a heterozygous 1 bp duplication and M20 
has a heterozygous 10 bp deletion confirmed by Sanger sequencing by SynthegoTM.  b) 
Predicted variant coding sequence using Mutalyzer (https://mutalyzer.nl/). Both variants lead 














Supplementary figure 2.2: HNRNPU+/- hCOs transcriptomic signature reproduced across 
experiments and isogenic mutant lines. a)  and b) Scatter plot of log2fc of significant 
HNRNPU+/- DEGs (FDR<.05) between two experiments (n=18 organoids (expt1) and 24 
organoids (expt2) ) and two isogenic mutant lines, D11 and M20 versus PGP1 controls (n=42 
organoids each). c) Geometric mean enrichment of gene sets between experiments and 


















Supplementary figure 2.3: Annotation of clusters in DIV45 hCOs. Clusters first separated 
into neuronal clusters by DCX, STMN2, GAP43 and proliferative and cortical precursor cells 
by VIM, NES and HES1. Cluster 0 was predominantly positive for neuronal markers but 
showed no specific enrichment of neuronal subtype markers or subtype specific 
neurotransmitters and were thus labeled as “noncommitted.” All other clusters were classified 
using enrichment of canonical markers and gene ontologies. Enriched genes generated using 
MAST conserved markers across D11, M20 and PGP1. ‘SCPN’ = sub-cortical projection 










Supplementary figure 2.4: HNRNPU expression in DIV45 hCOs. Average Expression of 
HNRNPU in annotated cell clusters shown using Seurat’s a) DotPlot and b) Violin Plot 
functions. For dot plot, size of circle shows percent of cells expressing HNRNPU mRNA 
transcripts, while the coloring shows average expressing. Average expression highest in 
NSCs, but no clear patterns of expression across cell types and HNRNPU is expressed in all 










Supplementary table 2.2: Significance testing of compositional differences in 
HNRNPU+/- hCOs. For each line, all five samples treated as independent. 
Directionally consistent significant or trending significant (<.05 or <.06) 






















Supplementary figure 2.5: Cross-species trancriptomic and epitranscriptomic comparisons. 
Literature search shows few attempts to compare transcriptomic or epitranscriptomic 
signature across human stem cell and mouse models of neurodevelopmental disorders. a) 
Searched for all papers that mentioned one of several descriptors of neurodevelopmental 
disorders and found 803 papers that include all three terms human, stem cell and mouse. b) 
Manual examination of 803 papers identified 3 papers with modestly robust comparison of 
dysregulated genes across species. Importantly, only two considered transcriptomic or 
epitranscriptomic patterns across all gene sets. Yoon et al. found consistent methylation 
signatures when looking at embryonic mice and 47-day-old organoids, while Seabra et al. did 
not find significant overlap looking at 8-week-old mice compared to a human in vitro system, 



























Supplementary table 2.3: HNRNPU+/- hCOs and Hnrnpufl/- E13 cortices show 
significant enrichment of co-dysregulated genes. Geometric mean enrichment 
(‘GME’) and corresponding p-values (‘pval’) are shown for all combinations of up 


















Supplementary figure 2.6: Enrichment of co-upregulated genes in two embryonic mouse 
models of HNRNPU deficiency. a) Cortical bulk RNA-seq of Constitutive knockout of 
Hnrnpu+/- results in 172 DEGs (FDR <.05, DESeq2), but no evidence of clustering in PC 
space by genotype or litter, while samples do cluster by gender. b) In heterozygous mice with 
a conditional truncating mutation in Hnrnpu (Hnrnpufl/- or Hnrnpufl/fl), cortical bulk RNA-seq 
shows clear stratification by genotype. c) No enrichment of sign mismatched gene sets 
between heterozygous mice from the two distinct mouse models, while there is ~3-fold 
enrichment of co-upregulated genes, elucidating some overlap of transcriptomic dysregulation 



















Supplementary figure 2.7: Downregulated genes in HNRNPU+/- hCOs upregulated in 
perinatal Hnrnpufl/- and Hnrnpufl/fl cortices. a) Best fit linear regression line shows evidence 
of negative correlation of log2 fold change of gene correlates in HNRNPU
+/- hCOs and 
perinatal heterozygous (left) and homozygous (right) conditional knockouts, while 
HNRNPU+/- dysregulation is positively correlated with embryonic homozyogotes (middle).  b) 
Both heterozygous (left) and homozygous (right) perinatal cortices show significant 
upregulation of genes downregulated in in HNRNPU+/- hCOs. Alternatively, embryonic 
homozyogtes (middle) show enrichment in both co-upregulated and co-downregulated genes, 
without any evidence of enrichment in sign reversed gene sets, suggesting partial reproduction 
of transcriptomic dysregulation across models. For analyses of perinatal heterozygotes, 














Supplementary figure 2.8: Developmental divergence of transcriptomic signature evident in 
Hnrnpu+/- mice. a) Positive correlation (R2 = .31) and significant ~6-fold enrichment in co-
downregulated genes between Hnrnpu+/- E13 and DIV45 HNRNPU+/- hCO DEGs. b) Negative 
slope (R2 = .15) and no evidence of significantly enriched discordant or concordant gene sets 
between DIV45 HNRNPU+/- DEGs and Hnrnpu+/- P0 DEGs (unadjusted pval<.05 use for P0 
due to absence of genes with FDR-adjusted significance). c) Genes downregulated in hCOs 
and upregulated in perinatal Hnrnpufl/- cortices predominantly upregulated in perinatal 
Hnrnpu+/- cortices (binomial distribution, p<.00001). 
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Chapter 3: Identifying synchrony phenotypes in vitro using 
multielectrode arrays 
Transcriptomic phenotypes may not correspond to prominent symptoms of patients 
suffering from neurodevelopmental disorders (‘NDDs’). In some instances, aberrant expression 
at the transcriptome level may not lead to similar proteomic dysfunction. When transcriptomic 
changes are recapitulated in the proteome, the disruption of certain subsets of genes still may not 
underlie prominent phenotypes seen in patients. Identifying functional phenotypes downstream 
of transcriptomic dysregulation may be utilized to validate transcriptomic differences underlie 
certain prominent symptoms seen in patients. Similarly, functional phenotypes potentially can be 
used to identify disease-relevant phenotypes and test potential therapies, with or without the 
identification of transcriptomic differences. A significant number of patients suffering from 
NDDs exhibit epileptic encephalopathies, which include disruptions of neural synchrony. Within 
this chapter, we aim to improve the capacity of in vitro systems to identify potentially disease-
relevant synchrony phenotypes in either mouse or human neural networks. In chapter 3a, we 
introduce topological techniques capable of identifying novel and complementary synchrony 
phenotypes in mouse models of certain epileptic encephalopathies. In chapter 3b, we attempt to 
generate networks capable of characterizing synchrony differences driven by excitatory / 




Chapter 3a: Identifying synchrony phenotypes in vitro using 
multielectrode arrays 
Introduction  
Multielectrode arrays (MEAs) have been used to effectively study activity patterns of neuronal 
populations in vitro (see e.g., Van Pelt 2004, Esposti 2007, Massobrio 2015, Kizner 2020, 
Soussou 2007). Traditionally, MEA approaches utilized single wells with a high density of 
electrodes (Hales 2010) or require ad hoc approaches in order to record from multiple MEAs 
simultaneously (van Bergen, 2003). More recently, multi-well MEA systems have been 
developed that are capable of recording simultaneously from a number of neuronal networks, 
ranging from 6-well to 96-well plates. Such MEA systems have identified aberrant network 
activity using in vitro models of certain epileptic encephalopathies (‘EEs’) (Gullo 2014, 
Raghavan 2012, Shore 2020, Ahn 2021, Amador 2020). However, while aberrant synchrony is 
definitive for epileptic encephalopathies, identifying robust synchrony phenotypes remains 
challenging. Reports often do not identify specific synchrony differences or only identify them in 
homozygote mice, which do not match the genotypes of patients (Shore 2020, Ahn 2021, 
Amador 2020). 
 
Importantly, network activity of wild-type cultures shows a limited number of active electrodes 
(Ahn 2021) or highly synchronized activity in primary mouse cultures (Shore 2020, Guiberson 
2018, Lignani 2013) inconsistent with in vivo activity patterns, where networks begin to 
desynchronize by the end of the second postnatal week (Golshani 2009). In rat cortical cultures, 
widespread synchronized firing was temporarily ablated by micropulses of acetylcholine, but 
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predominantly correlated activity invariably reemerged (Kaufman 2014). We hypothesized high 
levels of synchrony may be confounding and experimental or computational innovation would be 
needed to identify more robust MEA synchrony phenotypes in vitro. 
  
Next generation MEA plates or readers, alternative culturing paradigms or novel post hoc 
computational tools may all improve capacity of MEAs. Herein, we focus on the latter approach, 
which may inform future experimental design. Several groups have developed computational 
tools to quantify several proxies for synchrony in MEA recordings designed to compare wild-
type and mutant networks (e.g., Gelfman 2018, Eisenman 2015, Lama 2018, Bradley 2018), 
however, none of these tools specifically considers how topology, as it relates to distance, affects 
synchrony in vitro.  
 
Small-world network topology was lost in cultured neurons following the addition of glutamate 
(Srinivas 2007); suggesting topological approaches may be useful in characterizing EEs in vitro. 
Similarly, calcium imaging of primary neurons exposed to methamphetamine led to aberrant 
assortativity, despite no differences in functional connectivity, suggesting topology specific 
phenotypes can be identified in vitro (Miller 2019). Topological approaches on MEAs often 
focus on singular networks and are not generally designed to compare mutant and wild-type 
cultures across a large number of wells (Gerhard 2011, Schroeter 2015, Pastore 2021).  Due to 
the high intrinsic variability of network activity on MEA, it is crucial to examine a large number 
of networks in order to identify reproducible network dynamics and synchrony differences 




Critically, topological phenotypes have been implicated in epilepsy in human patients. Using 
intracranial recordings, a breakdown of global and local topology is seen at seizure onset in 
humans (Kramer 2008). Similarly, intracranial EEGs identified that slight changes in network 
topology could underlie the recurrence of epileptic seizures (Wang 2017).  Despite evidence of 
topology in distinct in vitro systems and the relevance of topological disruption to epilepsy, a set 
of tools capable of identifying aberrant topology in genetic mouse models of epilepsy, 
independent of global synchrony differences, is lacking. 
 
We first show that nearby electrodes have more synchronous firing than more distant electrode 
pairs using two distinct measurements of local topology, the Local Synchrony Coefficient 
(‘LSC’) and the Local Burst Synchrony Coefficient (‘LBSC’). The measures extend two 
previously described quantifications of synchrony, the Spike-Time Tiling Coefficient (‘STTC’) 
and Mutual Information, by generating a plate-level statistic that quantifies the relationship 
between those synchrony features and the distance between electrodes. We then show LSC and 
LBSC are capable of identifying novel phenotypes in vitro independent of global synchrony 
phenotypes in the presence of GABAergic and Glutamatergic modulators, as well as in models 
of three distinct NDDs. Further, we adapted a commonly used topological approach, the 
clustering coefficient, to identify discordant synchrony phenotypes in mice heterozygous and 
homozygous for a gain-of-function mutation in Grin2a early in development. 
2 Methods 
Generally, this paper focuses on first characterizing the developmental trajectory of the 
relationship between distance and synchrony in murine cortical neuronal networks. Then, we 
utilize broadly acting therapeutics to show enrichment of local synchrony can be ablated. 
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Further, we investigate whether such topological measures increase the dynamic range of MEAs 
to identify novel phenotypes independent of existing measures of synchrony. Below, we outline 
the experimental MEA paradigm used to generate all data herein, describe the existing synchrony 
measures and the topological methods used to assess the networks and finally we describe the 
drug-dosing paradigm and genetic mouse models used to validate the potential of such analyses. 
 
2.1 Mice, Husbandry and Genotyping 
All data were generated using mice bred and maintained at Columbia University Irving Medical 
Center under IACUC approval and all mouse work was in accordance with state and federal 
Animal Welfare Acts and Public Health Services policies. Mice were housed in ventilated cages 
at controlled temperature (22–23oC), humidity (~60%), and 12h:12h light:dark cycles. Mice ate 
regular chow and water without restriction. 
 
Cortical networks from Grin2aS644G , described in Amador 2020, were re-analyzed. Networks 
from Hnrnpu+/113DEL mutant mice, which were generated on the C57BL/6NJ background and 
characterized previously (Dugger 2020), were assessed. Stxbp1 targeted mice (C57BL/6N-
Stxbp1tm1a(EUCOMM)Hmgu/JMmucd) were obtained from The Jackson Labs and maintained 
on the C57BL/6NJ background.  Cortical networks from Stxbp1+/- and wild-type littermate 
controls were assessed on the F1 hybrid background B6NJ/FVB.  
 
Grin2aS644G and Hnrnpu+/113DEL mutant mice were genotyped as previously described (Amador 
2020, Dugger 2020). Stxbp1+/- mice were genotyped using allele-specific PCR amplification 
resulting in a 444bp wild-type band and 300bp mutant band  (WT F: CAA ACT CAG ACT GGC 
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CTA TGA, WT R: AGT AAA GCA GGC AAA GAA TGC, MUT F: CGG TCG CTA CCA 
TTA CCA GT, MUT R: TGC AAA GAG AGG TTG GTT TGA). 
 
2.2 MEA Experimental Design and Statistical Analyses 
2.2.1 Primary Neuron Culture 
For all MEA experiments, cortical neuron dissociation, plating and network maintenance were 
performed similarly. Following genotyping, cortices from wild-type and mutant littermates were 
first separated from the rest of P0 mouse brains in Hibernate A medium (Thermo Fisher). 
Cortices were then dissociated into single cells via incubation in 20 U/mL Papain/DNase 
(Worthington) for 15-20 minutes at 37°C. Following manual trituration using a P1000 tip, cells 
were centrifuged at 300 x g for 5 minutes and washed in 1X PBS. Pellets were then resuspended 
in Neurobasal-A (Life Technologies) supplemented with 1% B27 (Life Technologies) or 1% B27 
Plus (Life Technologies), 1% GlutaMax (Life Technologies), 1% HEPES, 1% 
Penicillin/Streptomycin, 1% fetal bovine serum (Gibco) and 5 µg/mL laminin. Live cells were 
counted using trypan blue and fifty thousand cells were plated in a 40-50 µl convex droplet onto 
wells of a 48-well MEA plate (Axion BioSystems) that had been pre-coated with 50 µg/mL poly-
D-lysine (Sigma) in either 0.1M borate buffer or H20, rinsed with PBS and dried for at least 1 h. 
The following day, 500 µl fresh media was added as described above, without laminin or fetal 
bovine serum.  
 
For all experiments, a 50% media change with Neurobasal-A, B27 or B27 Plus, GlutaMax, 
HEPES and P/S occurred every two days. Chronic drug dosing experiments were performed by 
adding the specified concentration of drug based on an approximation of 500 ul of media per 
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well. Drug dosing was performed following 50% media change on DIV 3 and 5 and compounds 
were serially diluted with 50% media changes for the remainder of experiments.  
 
Cultures were allowed to equilibrate for 10 min at 37°C in a carbogen mixture of 95% O2, 5% 
CO2 before activity recordings. Recordings were for 10 minutes long and were always performed 
immediately prior to media changes using Axion BioSystems Maestro 768 channel amplifier and 
Axion Integrated Studios software (v2.4). A Butterworth bandpass filter (200-3000 Hx) and 7X 
standard deviation adaptive threshold spike detector were used to generate raw data and spike 
files.  
 
2.2.2 Global Synchrony  
Following generation of raw data using Axion’s software, the meaRtools pipeline was used to 
analyze a wide variety of features, including number of active electrodes, mean firing rate, 
mutual information and spike-time tiling coefficient ‘STTC’ (Gelfman 2018). The topological 
analyses within this work incorporate spatial considerations to a subset of measures of synchrony 
from the meaRtools pipeline. Importantly, STTC and Mutual Information assess synchrony 
through distinct algorithms. While both algorithms rely on pairwise correlations between 
electrodes, the mathematical approaches are quite different. Broadly, STTC quantifies the 
proportion of spikes in electrode B that fall within a specified time window of a spike in 
electrode A and uses this as a proxy for correlation of activity in two electrodes (Cutts 2014). 
Alternatively, Mutual Information only considers portions of the spike-train with >75th percentile 
levels of activity and considers these bins of activity ‘bursts.’ Then, the algorithm generates a 
proxy for correlated activity by giving each bin of a time a value of 1 if both electrodes are 
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simultaneously bursting or not bursting and a 0 otherwise. Thus, while both measures can be 
broadly used as a measure of synchronous firing in vitro, they are distinct and may diverge in 
direction in certain disease models.  
 
2.2.3 Local Synchrony Coefficient 
Local synchrony coefficient is a topological measure that quantifies how dependent the strength 
of pairwise STTCs is on the distance between two electrodes. First, all pairwise STTCs of active 
electrodes are generated. Then, a histogram is generated with the STTCs of all active electrode 
pairs across all wells within a plate are binned by distance between the electrodes. For each plate, 
a linear regression line is fit to the histogram and the slope of the linear regression line is 
extracted. Finally, the local synchrony coefficient ‘LSC’ is generated by multiplying the slope by 
-10,000. Thus, an increase in STTC for closer electrodes would result in a value greater than 0. 
 
2.2.4 Local Clustering Coefficient 
Clustering coefficients are a commonly used method within graph theory to measure the 
cohesion of a theoretical network (Chalancon 2013). More recently, clustering coefficients have 
been used to assess network dysfunction in epileptic patients (Pedersen 2015, Paldino 2017). 
Further, in high-density cultured neurons in single well MEAs, a form of clustering coefficient 
showed alterations in topology as the networks matured (Downes 2012). Here, we integrate the 





Broadly, a clustering coefficient is the proportion of nodes in a graph that are considered 
‘connected.’ For the LCC, we restrict our analyses to neighboring electrodes, defined by 
horizontal, vertical and diagonal neighbors (200um, 200um, 282.84um). For each electrode, the 
pairwise STTCs to all neighbors are considered and the two electrodes are considered connected 
if the pairwise STTC surpasses a threshold of 0.5. Then, for each electrode a clustering 
coefficient is determined by the proportion of neighboring electrodes that are connected. For 
each well, a single LCC is generating by averaging the LCC of all active electrodes. For this 
measure, the distribution of LCCs across wells is considered for downstream analyses. 
 
2.2.5 Local Burst Synchrony Coefficient 
The Local Burst Synchrony Coefficient (‘LBSC’) is similar to the LSC in determining the 
difference in strength of connectivity between nearby and more distant electrodes. Importantly, 
the LBSC leverages the Mutual Information algorithm from meaRtools that quantifies the 
correlation of bursting activity between electrodes. Specifically, let NEIGHBORS equal the 
aggregated pairwise Mutual Information statistics of all vertical, horizontal and diagonal 
neighbors of a given well. Further, let STRANGERS equal aggregated pairwise Mutual 
Information statistics of an electrode to all other electrodes in the well, excluding vertical, 
horizontal and diagonal neighbors. We then calculate the LBSC simply with a percent increase 
calculation. LBSC = (NEIGHBORS – STRANGERS / NEIGHBORS) * 100. As with the LSC, 
we generate a plate level value and downstream analyses are performed with a single value per 
plate.  
 
2.2.6 Statistical Analyses 
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The LSC and LBSC were first used to determine whether or not a topological approach to 
synchrony in vitro was applicable in 48-well MEA plates with just 16 electrodes per well. To 
determine the presence or absence of enriched synchrony in neighboring networks, 10 litters with 
220 wild-type wells were assessed. For both LSC and LBSC, a single plate level statistic was 
generated for each of the 10 litters. A one-sided Mann-Whitney p-value was used to test whether 
LSC and LBSC reject the null hypothesis of no enrichment of local synchrony. For comparisons 
between wild-type and mutant or drug dosed conditions, a two-sided Mann-Whitney test was 
used to generate a p-value.  
 
Unlike the LSC and LBSC, the LCC does not utilize a single plate-level statistic. Thus, statistical 
testing instead relied on a comparison of distributions. Specifically, a single plate level p-value 
was generated using an earth mover’s distance (Urbanek 2015) calculation between wild-type 
and mutant or drug dosed conditions. Then, a combined p-value was generated using Stouffer’s 
combined p-value method. When comparing significance of LCC to time-matched STTC, an 
identical one-sided Stouffer’s combined p-value was used. For all combined p-values, singular p-
values were constrained with a minimum of .0001 or maximum of .9999.  
 
2.2.7 Comparison to Non-Topological Synchrony Features 
Importantly, all topological analyses described are extensions of existing measures of synchrony, 
STTC and Mutual Information. Thus, when determining the existence of topological phenotypes 
in models of disease or therapeutic intervention, we similarly assessed whether or not mean 
firing rate, mean STTC or Mutual Information more generally showed correlated disruption. To 
this end, we used meaRtools to generate all of these features as previously described and 
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available on CRAN (https://cran.r-project.org/web/packages/meaRtools/index.html). When 
compared with LSC and LBSC, the distributions of plate-matched mean STTC and mutual 
information were extracted and p-values were identically generated using a two-sided Mann-
Whitney test.  
2.2.8 Identification of spike-and-wave discharges (‘SWDs’) in Stxbp1+/- mice 
Electrodes were implanted in 8- to 10-week-old F1 hybrid wild-type and Stxbp1+/- mice, as 
previously described (Asinof 2015). Briefly, three silver wire electrodes were placed 1 mm 
rostral to bregma and 1 mm to either side of midline subdurally, with a fourth electrode over the 
cerebellum as reference. An 8 research amplifier (Natus, Inc) was used to acquire signal in 48-hr 
continuous recordings. NeuroWorks software (Natus, Inc) was used to examine referential 
montages. SWDs were scored manually. Events shorter than 1s, or with amplitudes less than 
twice the adjacent background, were excluded from analysis. 
 
3 Results 
3.1 Network Topology 
For initial characterization of presence or absence of enriched synchrony in nearby electrodes, 
we considered 10 litters of wild-type networks. Recording schedules for MEA plates varied, but 
all datasets included recordings as early as DIV11 and continued through at least DIV21 with 
recordings at least every other day. Thus, for all analyses herein, DIVs 11 through 21 were 
considered. 
 
First, we tested whether or not there was increased synchrony for nearby electrodes in wild-type 
networks (figure 3.1). To this end, we considered two previously described distinct measures of 
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synchrony Mutual Information and STTC (Gelfman 2018). Mutual Information considers how 
frequently electrodes burst together, while STTC looks at the overall pairwise correlation of 
spike-trains using a moving time window. Importantly, Mutual Information and STTC do not 
necessarily increase or decrease together. Similarly, when several measures of synchrony are 
considered simultaneously, there is significant variation in sensitivity and direction of 
phenotypes in the presence of GABA and AMPA modulators (Bader 2017, Eisenman 2015). We 
leveraged both of these calculations to generate two distinct topological-based synchrony 
measures – the Local Synchrony Coefficient (LSC) and the Local Bursting Synchrony 
Coefficient (LBSC).  
 
The LSC generates a positive value when the pairwise STTCs is increased for closer electrodes. 
Alternatively, the LBSC generates a positive value when the average MI from a given electrode 
to all neighboring electrodes is greater than the average MI of all other electrodes (figure 
3.1a’,b’). Thus, the LSC and LBSC used two distinct approaches to quantify the relationship 
between distance and synchrony within MEAs. With both two measures, we were able to 
identify enriched local synchrony in 48-well MEAs (figure 3.1a’’,b’’).  
 
Importantly, the developmental timeline of enriched local synchrony varies depending on 
topological approach. For example, the LSC does not show clear enrichment of local networks at 
DIV11, while there is evidence of increased local synchrony using LBSC. While both measures 
elucidate enriched local synchrony, it must be noted that local topology is not apparent in all 
plates at all later time points, with the presence of negative LSC and LBSC values at DIV21 
(figure 3.1a’’,b’’). Thus, identification of topological phenotypes may be more robust for certain 
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developmental time windows in vitro, and a larger number of plates may be required to identify 
phenotypes in older cultures. 
 
3.2 Network topology disrupted through chronic drug-dosing of MgCl and Muscimol 
We next considered to what extent network topology and development can be perturbed by 
treating wild-type networks with compounds known to modulate certain subtypes of neuronal 
activity. We focused on early perturbation of cortical networks to examine whether disruption of 
activity had longitudinal or long-lasting effects on network activity. We tested compounds 
known to promote Glutamatergic (MgCl) or GABAergic (Muscimol) activity (figure 3.2a), 
processes known to have significant roles in neurodevelopment (Wu 2015, Wang 2009, 
Luhmann 2016, Ojeda 2019). 
 
Early, chronic dosing of both MgCl and Muscimol resulted in aberrant topology in vitro. MgCl 
showed significant reductions in LBSC concordant with similar differences in Mutual 
Information (figure 3.2b,c). Muscimol addition results in a consistent, similar ablation of 
network topology at earlier time points, without a corresponding phenotype in overall STTC 
(figure 3.2b,c). Thus, incorporating topology into synchrony metrics is capable of identifying 
phenotypes both concordant and discordant with existing features. 
 
In mature time points, evidence of enriched local synchrony in Muscimol treated wells re-
emerges. Early ablation of topology in Muscimol-treated wells may be impacted by low levels of 
muscimol remaining in culture. Alternatively, networks may recover during development or 
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sensitivity to topological phenotypes may be limited in mature networks by high overall levels of 
synchrony.  
 
3.3 LBSC and LSC identify novel phenotypes in models of neurodevelopmental disease 
Next, we considered whether or not topological analyses can identify phenotypes in vitro 
complimentary to existing synchrony measures. To this end, we considered three distinct mouse 
models of neurodevelopmental disease (Described in Section 2.1). Loss of function mutations in 
STXBP1 (Saitsu 2012) and HNRNPU (Epi4K Consortium 2012, Yates 2017) have both been 
identified as pathogenic in severe epileptic encephalopathies. Similarly, a patient specific gain-
of-function mutation in GRIN2A (S644G) was generated and characterized in a mouse model 
both in vivo and in vitro (Amador 2020).  
 
We obtained and characterized the seizure activity via video-EEG of a constitutive Stxbp1 
knockout mouse model generated as part of the Knockout Mouse Phenotyping program 
(KOMP).  Similar to other genetic mouse models of STXBP1 haploinsufficiency (Kovacevic 
2018, Chen 2020), KOMP Stxbp1+/- mice displayed a preponderance of absence seizure-like 
spike-and-wave discharges with increased discharges during dark periods (supplementary figure 
3.1). While there was no evidence of spontaneous seizures, the Hnrnpu haploinsufficient mice 
exhibited reduced seizure thresholds (Dugger 2020), and Grin2aS644G heterozygotes and 
homozygotes showed resistance to electrically induced seizures and lethal tonic-clonic seizures, 
respectively (Amador 2020). Stxbp1-/- and Hnrnpu-/- networks were not generated, since 




Hnrnpu+/- and Stxbp1+/- cortical networks were first assessed for an array of features outlined in 
meaRtools (Gelfman 2018). For Stxbp1+/- networks, consistent disruption in at least 3 out of 4 
plates was seen for several features, including all litters displaying an increase in spikes in bursts 
(supplementary table 3.1). Confoundingly, certain features in both Hnrnpu+/- and Stxbp1+/- 
cortical networks showed highly significant increases in one litter as well as a discordant 
decrease in biological replicates. Importantly, such discordance is especially pronounced in 
Hnrnpu+/- networks, with discordant results in 9 out of 13 features, suggesting MEA recordings 
may be particularly limited in their specificity for mouse models with more mild in vivo 
phenotypes. Thus, the variability within MEA systems likely minimizes their throughput, while 
certain phenotypes with large effect size may be strong enough to remain robust across 
biological replicates.  
 
We then analyzed Hnrnpu+/- and Stxbp1+/- cortical networks, alongside previously described 
Grin2aS644G heterozygote and homozygote cultures, using the LSC and LBSC to determine 
whether or not such topological measures can improve upon conventional measures of 
synchrony, such as STTC and MI. In Hnrnpu+/- mice, LSC shows aberrant topology in mutant 
networks independent of mean STTC (figure 3.3c). Using the LBSC, aberrant topology is seen in 
a mouse model of Stxbp1 haploinsufficiency alongside a corresponding increase in mutual 
information (figure 3.3a). Importantly, a significant increase in mutual information alone is not 
sufficient to generate a topological phenotype, as there is no significant difference in LBSC in 
Grin2ap.Ser644Gly/p.Ser644Gly mice (figure 3.3c). Thus, topological approaches identify synchrony 
phenotypes that are complementary to existing measures and capable of identifying synchrony 




3.3 Local Clustering Coefficient identifies early disruption in Grin2a+/p.Ser644Gly mice 
Once we established incorporating distance between electrodes compliments and extends 
existing synchrony measures in cortical MEAs, we aimed to leverage graph theory to generate 
additional topological measures capable of identifying disease phenotypes in vitro. To this end, 
we generated a Local Clustering Coefficient (‘LCC’), a simple adaptation of the commonly used 
clustering coefficient (figure 3.4a). We then assessed whether or not there was aberrant topology 
in mice heterozygous or homozygous for the S644G mutation in Grin2a. Importantly, significant 
synchrony phenotypes were identified in homozygous mice, but not in heterozygotes (Amador 
2020). Here, we additionally identify synchrony phenotypes in heterozygotes, finding significant 
reduction in local clustering early in development in heterozygote, Grin2a+/p.Ser644Gly, mice, 
without a reduction using global synchrony metrics (figure 3.4b,c).  
 
The LCC also allows for visualization of how networks change over time. In a representative 
plate, a wide spectrum of LCCs is seen at DIV11, but almost all pairs of electrodes surpass the 
‘connected’ threshold by DIV15 for all conditions (figure 3.4c). Such hyper synchronization can 
also be seen as the mean STTC for wild-type and mutant mice begin to converge by DIV21 
(figure 3.4b). The rapid saturation of LCC suggests the feature is best suited to identify early 




The topological measurements presented in this work were generated with the intention to both 
examine the presence of increased synchrony of neighboring electrodes in a medium-throughput 
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MEA system and determine whether or not such measures are capable of identifying disease-
relevant phenotypes. We leveraged the existence of previously described measures of synchrony 
and adapted a commonly used graph theory measure to assess a set of drug perturbations and 
models of neurodevelopmental disease.  
 
Importantly, while topology has been well described in many systems, most measures of 
topology both in vivo and in vitro rely on significantly more than 16 electrodes (see e.g., Eytan 
2006, Marconi 2012, Campos 2018, Pastore 2018). By identifying the presence of enriched local 
synchrony in 48-well MEA plates, we established that such systems with limited electrodes can 
be utilized for a wide array of topological analyses, including, but not limited to, those described 
within this work. Consistent with the divergent developmental patterns of STTC and Mutual 
Information, the pattern of enrichment of local synchrony using the LSC and LBSC suggest the 
measures are identifying distinct topological features. Neuronal networks are incredibly 
complex, as are the molecular mechanisms that generate specific topological patterns. Within 
this work we do not address the molecular underpinnings driving local topology in vitro and 
further molecular biology experiments may be required to better understand the drivers of 
increases of LSC and LBSC.  
 
While we do not address molecular mechanisms, we do begin to try and understand what broad 
activity-dependent processes may drive aberrant topology in vitro. We have shown that early 
perturbation of both Glutamatergic and GABAergic activity in vitro ablates certain elements of 
local topology. When considered in combination with other synchrony features, investigators 
may be able to better streamline which hypotheses to consider and better focus molecular 
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experiments. A more robust analysis on how chronic and acute dosing of certain drugs impact 
topological measures would further the work within this study and provide a wider array of 
topology and synchrony phenotypes that may phenocopy certain developmental diseases. 
 
The measures described (LSC, LBSC and LCC) increase the capacity of MEAs to identify 
screenable phenotypes that may lead to therapeutics for patients suffering from an array of 
NDDs. All tools are optimized to be compared across plates and conditions and 48-well plates 
allow for the testing of several therapeutic compounds concurrently. Using these measures, we 
were able to identify novel topological phenotypes in three distinct disease models, which are 
complementary to existing synchrony measures.  
 
However, all topological phenotypes discussed are sensitive to time-point, with some wild-type 
showing no evidence of increased local synchrony at certain DIVs, potentially in part due to the 
hyper-synchronization of primary cortical networks on MEAs. Further, in some cases aberrant 
topology may only be identified with one of the features described here. Given the significant 
plate to plate variability across conventional features in MEAs, singular topological phenotypes 
may be artifacts in certain circumstances. Further, high levels of global synchrony may limit the 
capacity to identify aberrant topology.  
 
The MEA system is limited by hyper-synchrony and high plate to plate variability, which 
reduces the throughput of therapeutic screens. Further improvements to experimental paradigms 
may be necessary for MEA systems to be used efficiently in drug development paradigms. Such 
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improvements may improve both the specificity and sensitivity of all MEA features, including 
the topological methods described and lead to more efficient drug development paradigms.  
 
We have generated a set of topological measures that complement and improve upon existing 
measures of synchrony and identify novel phenotypes in a subset of NDDs. For a given disease 
model, it is often difficult a priori to predict which features will be relevant to human disease. In 
some disease models, low- to medium-throughput therapeutic screens to reverse topological 

































Figure 3.1: Topology in MEAs. a) Schematic of meaRtools calculation of STTC. For each 
electrode, an STTC value is generated by averaging the STTC of all active electrode pairs. a’) 
Calculation of local synchrony coefficient (‘LSC’). LSC is calculated by generating pairwise 
STTCs for all electrode pairs and regressing based on distance. a’’) LSC shows enriched local 
topology emerging at DIV13. b) Schematic of meaRtools calculation of mutual information 
(‘MI’). For each electrode, a singular value is calculated by averaging pairwise MI of all 
neighboring electrodes. b’) Calculation of local burst synchrony coefficient (‘LBSC’). LBSC 
is calculated by quantifying the percent change between the mutual information of 
neighboring and more distant electrodes. b’’) LBSC shows enriched local synchrony across 

















Figure 3.2: Aberrant Topology in MEAs Treated with Muscimol and MgCl. a) Description of 
experimental approach for early perturbation of activity. b) Chronic dosing with MgCl 
increases synchrony, as quantified by existing metrics. MgCl dosing leads to an increase in 
MI across all time points and an increase in STTC for early time points (DIVs 11,13,15). c) 
Aberrant topology identified in MgCL and Muscimol treated networks is complementary to 
existing synchrony metrics. MgCl shows aberrant bursting topology concordant with 
disrupted MI, but no difference in LSC at early or late time points. Muscimol treatment 
























Figure 3.3: Topological Measures Identify Novel, Complimentary Phenotypes in Mouse 
Models of Neurodevelopmental Disorders. a) In Stxbp1+/- mice, LBSC and Mutual 
Information show significant and trending significant differences, respectively. b) In 
Grin2a homozygotes, significant differences in Mutual Information does not result in 
aberrant bursting topology. c) In Hnrnpu+/- mice, disruption of local synchrony despite no 
difference in mean STTC (n=6 plates, 144 wells). Across three models, incorporating 





















Figure 3.4: Local Clustering Coefficient (‘LCC’) Identifies Novel Phenotype in 
Grin2ap.Ser644Gly/+ Mice. a) LCC is generated by considering all electrode pairs with an STTC 
>0.5 as ‘connected.’ Local clustering coefficient for all electrodes is equal to the proportion of 
neighboring electrodes that are connected. b) Synchrony differences in homozygous mice at 
DIV11 identified in homozygous, but not heterozygous, mice (n = 5 plates, 14-16 wells per 
plate). c) LCC identifies aberrant topology in both Grin2ap.Ser644Gly/+ and 
Grin2ap.Ser644Gly/p.Ser644Gly mice at DIV11. All conditions become hyper-connected by DIV15. 



















Supplementary table 3.1: MEA Characterization of Hnrnpu and Stxbp1 haploinsufficiency 
in primary cortical cultures. Permutation p-values and the direction of change listed across 13 
features analyzed using meaRtools software. ”nAE” = number of active electrodes. 
“MFR/nAE” = Mean firing rate per active electrode. “Mean Dur of Bursts” = Mean duration 
of bursts. “% spikes in NS” = percentage of spikes in networks spikes. “mean spikes in NS” = 
average number of spikes in a network spike. Plate to plate variability especially apparent in 
Hnrnpu+/- networks, with opposing significant differences in 9 out of 13 features considered.    






















Supplementary figure 3.1: Spike-and-wave Discharges in Stxbp1+/- mice. Stxbp1+/- mice 
display absence seizure-like EEG phenotypes in vivo. Significant number of SWDs in both 
light and dark, with higher frequency, shorter discharges in the dark period. a) Example traces 
displaying SWDs from electrodes implanted in wild-type and Stxbp1+/- mice.  “BL” = back 
left. “FR” = front right. “FL”. b) Duration of all identified SWDs in 7 Stxbp1+/- mice and 3 
wild-type litter mates. c) Average number of SWDs in light and dark periods over 48 hours (n 
= 7 Stxbp1+/-, 3 wildtype).  





Chapter 3b: GABAergic interneurons remain functionally 
immature in vitro after 90 days 
Introduction 
As discussed above, topological measures can improve the sensitivity of murine MEAs to 
identify electrophysiological phenotypes in vitro for certain neurodevelopmental diseases. 
However, murine cortical networks show high, potentially confounding levels of synchrony and 
a significant number of wells and plates are often needed to identify any phenotypes in certain 
models. Further, mouse models may not recapitulate disease-relevant electrophysiological 
phenotypes seen in patients due to species-specific effects. Therefore, we aimed to investigate 
synchrony in human networks, using stem-cell derived networks. 
 
Many distinct techniques exist to generate neurons from human stem cells ranging from 2D 
monolayers to 3D organoids to genetic induction-based protocols where forced overexpression 
of specific transcription factors generate distinct neuronal subtypes (e.g., Chambers 2009, Shi 
2012, Maroof 2013, Liu 2013, Xiang 2017, Tsunemoto 2018). This set of protocols, along with 
many others, tend to predominantly generate specific neuronal subtypes. Importantly, certain 
protocols that generate cortical glutamatergic neuron progenitors and GABAergic interneuron 
progenitors differ by the extent and timing of WNT inhibition and Sonic Hedgehog signaling 
(Shi 2012, Liu 2013). Thus, with minimal optimization and similar culturing conditions, 
excitatory and inhibitory progenitors can be generated in parallel. 
 
The balance of excitatory and inhibitory tone has been implicated in a wide number of 
neurodevelopmental disorders (Bozzi 2018, Lopatina 2019). Further, certain populations of 
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inhibitory neurons are primate-specific and there is greater diversity of cortical inhibitory 
neurons in humans than in rodents (Kelsom 2013, Radonjic 2014, Wang 2015). Both the 
specification of subtypes and functional maturation of GABAergic interneurons are driven by 
activity-dependent processes (Chattopadhyaya 2011, Lehman 2012, Pan 2019). Thus, we 
specifically aimed to generate neuronal networks with physiologically relevant proportions 
(Sultan 2018) of excitatory (~70-80%) and inhibitory neurons (~20-30%), hypothesizing such 
networks may lead to increased functional maturity and elucidate the impact of E/I imbalance on 
developing networks.  
 
Surprisingly, overall activity, synchronicity and synaptic E/I balance did not vary in networks 
with more physiological proportions of excitatory and inhibitory neurons versus excitatory 
networks alone. We show that while existing protocols generate highly enriched progenitor 
populations, inhibitory neurons are slow to develop functionally mature inhibitory synapses in 
vitro (within the 90-day time frame studied here), whereas excitatory neurons developed 
functionally mature synaptic responses within this time frame, as seen in other studies. The lack 
of upregulation of inhibitory synaptic markers may suggest inhibitory populations require more 
time or additional perturbation in order to contribute to more divergence between proportional 
networks and excitatory enriched networks. Thus, prolonged experimental timelines or 
alternative protocols to generate mature GABAergic populations may be necessary to more 
efficiently modulate functional inhibitory tone in human systems.  
 
Methods 
Stem cell line generation and expansion 
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This study was performed according to approved IRB guidelines, with a donor’s’ consent, and 
approved under Columbia University. Dermal biopsies were collected from a healthy female donor 
(Subject 1F1-5).  Dermal fibroblasts and hiPSCs were generated as previously described (Boland 
2017) with slight modifications. Fibroblasts were reprogrammed by non-integrative Sendai viral 
delivery of POU5F1, SOX2, KLF4, and c-MYC using CytoTune-iPS 2.0 (Thermo Fisher). Cells 
were transduced with viral particles and maintained in fibroblast medium (DMEM, 10% FBS, 1X 
GlutaMax, 1X non-essential amino acids). One week post-transduction, cells (1,000/cm2) were 
plated on a feeder layer of mitotically-inactivated mouse embryonic fibroblasts and the following 
day medium was switched to DMEM/F12, 20% Knockout Serum Replacement (Thermo Fisher), 
1X Glutamax, 1X non-essential amino acids, 0.1mM β-mercaptoethanol, and 25ng/ml bFGF. After 
3 weeks, colonies exhibiting characteristic hiPSC morphology were manually picked and 
expanded on Geltrex LDEV-Free (Thermo Fisher) coated plates (1:200 dilution of stock) in TeSR-
E8 medium (Stem Cell Technologies) at 37ºC, 5% CO2 and ambient oxygen levels. Stem cells 
were passaged every 3-4 days with 5 mM EDTA and regularly tested for mycoplasma.  
 
Differentiation into Excitatory and Inhibitory Progenitors 
Excitatory and inhibitory neurons were generated based on adapted versions of previously 
described protocols (Shi 2012, Liu 2013, Maroof 2013). Cells were plated at 8.5-9.5 x 105 cells 
per well of a Geltrex (1:200)-coated 12-well plate in Essential 8 medium (Gibco) supplemented 
with ROCK inhibitor (Y-27632, STEMCELL Technologies). The following morning, media was 
replaced with Neural Induction medium, which consists of progenitor expansion medium  
[Neurobasal (ThermoFisher), 1X N-2, 1X B-27, 1X L-glutamine, 1X NEAA] supplemented with 
10 µM SB431452 and 1 µM Dorsomorphin (DM). For inhibitory cultures, the Wnt inhibitor 
XAV939 (2 µM) is additionally added during neuronal induction. Following 8 days of neural 
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induction, progenitor expansion medium is used through day 25 for excitatory cultures. 
Inhibitory cultures receive progenitor expansion media from days 8-10, which is then 
supplemented with recombinant Sonic Hedgehog (5 nM) and purmorphamine (1 µM) for days 




On day 25, progenitors are dissociated into single cells with Papain and plated on PDL-coated 
12-well plates with ~600-800K cells per well in progenitor expansion media supplemented with 
Laminin (2 µg/ml) and ROCK inhibitor. The following day, neuronal progenitors are fed with 
maturation media, consisting of progenitor expansion media supplemented with 10 µM Vitamin 
C, 20 µg/ml BDNF, 20 µg/ml GDNF, 125 µM cAMP, 10 µM DAPT and 1X 
Penicillin/Streptomycin. 50% media changes are performed three times a week through day 40.  
 
Plating for electrophysiological experiments 
On day 40, neurons are plated alongside murine astrocytes onto either 15 mm cover slips for 
patch clamp or into wells of a 48-well MEA plate (5 x 104 neurons, 1 x 104 astrocytes in a 50 µl 
droplet). For ‘proportional’ MEA cultures, 3.5 x 104  excitatory neurons and 1.5 x 104 inhibitory 
neurons are plated.  
 
Patch Clamp 
To assess synaptic activity, electrophysiological recordings were carried out by plating DIV40 
cultures with 100K neurons and 50K astrocytes on 15 mm diameter glass coverslips and 
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allowing networks mature through DIV80. Recordings were made in voltage clamp whole-cell 
configuration using a Multiclamp 700B amplifier and a Digidata 1550 digital-to-analogue 
converter (both from Molecular Devices) at a 10 kHz sample frequency. The external recording 
solution contained (in mM): NaCl 145, KCl 5, HEPES 10, Glucose 10, CaCl2 2, MgCl2 2, 0.001 
tetrodotoxin, at pH 7.3 adjusted with NaOH, and osmolality adjusted to 325 mOsm using 
sucrose. A cesium-based pipette solution contained (in mM): cesium methanesulfonate 130, 
sodium methanesulfonate 10, EGTA 10, CaCl2 1, HEPES 10, TEA-Cl 10, MgATP 5, Na2GTP 
0.5, QX-314 5, at pH 7.2 adjusted with CsOH, and osmolality adjusted to 290 mOsm with 
sucrose. Pipettes had final resistance of approximately 5 ΜΩ when filled with internal solution. 
Uncompensated series resistance was < 15 ΜΩ during recording. Series resistance and 
membrane capacitance were electrically compensated to approximately 70%. Miniature 
excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents 
(mIPSCs) were recorded from the same cell by holding the cells at -60 and 0 mV, respectively. 
Recordings were acquired for a period of 5 minutes. All recordings were carried out at room 
temperature (21 – 23 °C). Miniature events were detected offline with Clampfit 10.7 software 
(Molecular Devices) using the template matching function and a minimum threshold of 5 
pA.  Each event was manually inspected to determine inclusion or rejection in analysis. Further 
analysis was carried out using R (www.R-project.org). 
 
MEA and RT-qPCR 
MEA cultures were fed three times a week with 50% neuronal maturation medium changes and 
were recorded prior to feedings through DIV90. 1% FBS was added once a week to maintain 
survival of murine astrocytes. On DIV90, RNA was extracted from 2 biological replicates per 
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condition, with each replicate consisting of pooling 3 wells. Graphs displaying active electrodes 
and the synchrony measurements Mutual Information, Spike-time tiling coefficient (‘STTC’) and 
Entropy were generated using meaRtools (Gelfman 2018). 
 
For day 30 RT-qPCR, three replicates were extracted from confluent 12 well plates. For all RT-
qPCR experiments, gene-specific FAM-conjugated Taqman probes were used in conjunction 
with VIC-conjugated GAPDH as an internal control. 2X TaqMan Fast Universal master mix was 
used and RNAse-free water was added up to 10 µl alongside 10 ng of cDNA. cDNA was 
generated using SuperScript IV.  
 
Results 
Efficient generation of excitatory and inhibitory progenitors using dual-SMAD inhibition 
We first generated excitatory-enriched and inhibitory-enriched progenitor populations by 
optimizing existing protocols. Briefly, excitatory and inhibitory progenitors were generated using 
dual-SMAD inhibition in monolayer cultures with a single aggregate passage at DIV18. 
Inhibitory populations included WNT inhibition alongside increased SHH-signaling from 
DIV10-25. After 25 days, excitatory populations showed widespread expression of dorsal 
telencephalon marker PAX6, while inhibitory populations showed highly enriched populations 
of medial ganglionic eminence marker NKX2.1 (figure 3.5). Further, RT-qPCR confirmed 
significant enrichment of PAX6 and NKX2.1 in excitatory and inhibitory populations respectively 
at day 25.  
 
Following induction of excitatory and inhibitory progenitor populations, we aimed to identify 
whether or not there was functional enrichment of inhibitory activity after several weeks of 
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maturation. Excitatory and inhibitory progenitors were plated on primary mouse astrocytes to 
increase synaptic activity (Lischka 2018) at DIV25 and were allowed to mature for several 
weeks. After 55 days of maturation (80 days total), we identified significant enrichment of 
miniature excitatory post-synaptic currents (mEPSCs) and miniature inhibitory post-synaptic 
currents (mIPSCs) in excitatory and inhibitory populations respectively (figure 3.6). 
 
‘Proportional’ networks develop similarly to excitatory-enriched networks in vitro 
After confirming appropriate generation of excitatory and inhibitory-enriched progenitor 
populations, we attempted to develop ‘proportional’ human networks (figure 3.7) by co-culturing 
excitatory (70%) and inhibitory (30%) progenitors at approximate physiological proportions 
(Sultan 2017). We then tracked the development of network activity over time using MEAs and 
found networks with inhibitory-enriched progenitors alone were hypoactive. However, 
excitatory-enriched and ‘proportional’ networks develop similarly, with no significant 
differences in number of active electrodes, mean firing rate or measures of synchrony (figure 
3.8).  
 
Surprisingly, the introduction of significant inhibitory populations at DIV25 did not materially 
affect network development. Thus, we examined the expression of a subset of canonical markers 
throughout excitatory and inhibitory neuron development to better understand the composition of 
‘proportional’ networks. Interestingly, proportional networks at DIV90 maintained significant 
upregulation of inhibitory progenitor markers, such as GSX2 and NKX2.1, but interestingly did 
not upregulate markers associated with maturing inhibitory neurons, such as LHX6 and 
PROX1(figure 3.9). Similarly, there was no evidence of upregulation of inhibitory synaptic 
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markers. When we quantified expression of GABAergic specific synaptic markers, we found no 
clear change in the ratio of inhibitory postsynaptic marker gephyrin to excitatory postsynaptic 
marker PSD95 or inhibitory presynaptic marker VGAT to STXBP1, a ubiquitously expressed 
presynaptic marker (figure 3.10).  
 
Discussion 
We aimed to generate and characterize the development of human neuronal networks with 
physiological proportions of major neuronal subtypes by co-culturing excitatory and inhibitory 
progenitor populations. Surprisingly, increasing the number of inhibitory progenitors did not 
functionally perturb expression of inhibitory synaptic markers or show clear changes to network 
development using MEAs. Further, continued expression of progenitor markers through DIV90 
suggests lack of functional maturation of inhibitory neurons in vitro.  
 
Importantly, inhibitory neurons in humans undergo protracted development and such extended 
timelines are hypothesized to contribute to increased complexity and cognitive flexibility in 
gyrencephalic brains (Kim 2021). Similar protracted development may be necessary to generate 
similarly complex, diverse, and functional inhibitory neurons in vitro. In fact, prior work has 
suggested that more mature inhibitory subtypes only appear after 4-5 months in vitro in both 
monolayer and 3D models (Maroof 2013, Nicholas 2013, Xiang 2017).   
 
The balance between excitation and inhibition is very tightly regulated in vivo, with pathway and 
brain region specific proportions of excitatory and inhibitory neurons, synapses and synaptic 
events (Turrigiano 2011, Naka 2015). Importantly, subtype-specific disruption of neural circuitry 
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can lead to disease. In both a mouse and human model of Dravet syndrome, a severe epileptic 
encephalopathy, specific disruption of inhibitory interneurons is found to underlie pathogenesis 
(Tai 2014, Sun 2016). Similar disruption of inhibitory circuitry has been implicated in a wide 
array of NDDs, including Autism Spectrum Disorders, Rett Syndrome and Angelman Syndrome 
(Rodriguez 2018). Thus, generating neuronal networks with functionally mature inhibitory 
networks may be essential to elucidating activity phenotypes in vitro for a subset of NDDs. 
 
We attempted to better understand the impact of inhibitory tone on human neuronal networks by 
co-culturing dorsal and ventral telencephalic-like progenitor populations. Further, we considered 
whether or not coculture with excitatory networks would lead to more rapid maturation of 
inhibitory subtypes, given evidence of activity-dependent maturation in vivo. However, after 90 
days in vitro, inhibitory and proportional cultures continued to show strong upregulation of early 
developmental markers without corresponding increases in more mature canonical and synaptic 
markers of inhibitory interneurons. Similarly, MEAs with more physiological proportions of 
excitatory and inhibitory neurons did not diverge significantly from excitatory-enriched cultures 
using conventional measures of synchrony.  
 
Critically, we only assessed networks through 90 days in vitro. Inhibitory neurons experience 
protracted development in vitro and in vivo and activity profiles of proportional networks may 
begin to diverge more significantly in older cultures as inhibitory neurons further mature. 
Identifying synchrony differences in human networks may similarly benefit from the topological 
measures described in chapter 3a. Excitatory, inhibitory and proportional networks all had 
significantly fewer active electrodes, STTC and MI than all mouse models analyzed within this 
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thesis. Identifying topological synchrony phenotypes relied on first characterizing topology in 
wild-type networks and identifying phenotypes that were robust across multiple independent 
experiments. Similarly, generating more excitatory, inhibitory and proportional networks may 
allow for identification of enriched synchrony for nearby electrodes and elucidate differences in 
synchrony inaccessible using conventional metrics. 
 
Finally, we considered a singular protocol for generating inhibitory neurons, whereas alternative 
monolayer (Maroof 2013, Nicholas 2013), 3D medial ganglionic eminence (‘MGE’) organoid 
(Xiang 2017) or induction based (Yang 2017, Barretto 2020) protocols may generate distinct 
populations of inhibitory neurons with different functional properties. More recently, an 
emphasis on inducing age and maturity on stem cell-derived neurons has emerged (Ziff 2018, 
Anderson 2021). Generating more functionally mature neuronal populations will be especially 
critical when attempting to identify patient-relevant neuronal activity phenotypes in certain 
diseases such as HNRNPU haploinsufficiency, where human organoids show consistent 











































Figure 3.5:  PAX6 and NKX2.1 are predominantly expressed 
in DIV30 NPCs derived from excitatory and inhibitory 
protocols, respectively. a) ICC and (b) RT-qPCR of DIV30 
cultures with dorsal forebrain (PAX6) and MGE (NKX2.1) 















Figure 3.6: Enrichment of appropriate synaptic currents in DIV80 neurons. Whole cell voltage clamp 
electrophysiology demonstrates enrichment of excitatory currents (mEPSC) in human neurons derived with 
excitatory protocol and inhibitory currents (mIPSC) in human neurons derived with our inhibitory protocol. a) 
Representative traces of mini excitatory and inhibitory synaptic currents from individual neurons generated using 
excitatory (top) or inhibitory (bottom) protocols. b) Quantification of proportion of mEPSCs (left) and mIPSCs 












Figure 3.7: Paradigm for characterizing human neuronal networks with physiological proportions of excitatory 







Figure 3.8: ‘Excitatory’ and ‘proportional’ networks develop similarly on MEAs. a) Representative MAP2-
staining of DIV90 human neuronal networks on MEAs. b) Excitatory-enriched, inhibitory enriched and 
proportional networks (70% excitatory progenitors, 30% inhibitory progenitors) were maintained on MEAs 
through DIV90 and basic phenotypes were assessed using meaRtools. Number of active electrodes (‘nae’), 
mean firing rate per active electrode and two synchrony measurements (mutual info and STTC) all showed no 
significant difference between excitatory and proportional networks. Inhibitory networks are hypoactive 












Figure 3.9: Markers of ganglionic eminences enriched in ‘inhibitory’ and ‘proportional’ networks. Ganglionic 
eminence markers (COUP-TFI, NKX2.1 GSX2), early emerging GABAergic progenitor and neuronal markers 
(DLX2, DLX5), maturing and migratory GABAergic markers (PROX1 and LHX2) and GABAergic marker 










Figure 3.10: RT-qPCR shows no enrichment of inhibitory synaptic markers in 90-day-old ‘proportional’ 
networks. mRNA expression of inhibitory and pan-neuronal presynaptic markers, VGAT and STXBP1 
respectively, were quantified alongside inhibitory and excitatory post-synaptic markers, GEPHYRIN and PSD95 




 Advancements over the past twenty years have allowed for cost-effective and rapid 
genome and exome sequencing. Many of these sequencings performed worldwide have been 
aggregated into large publicly available databases. Further, medical and scientific professionals 
have leveraged such constantly expanding publicly available databases to provide genetic 
diagnoses for patients. Already, the benefits of extensive sequencing, publicly available data and 
genetic diagnosis are readily apparent when considering the impacts on patient care across 
medical indications, including developmental disorders.  
 Between 2011 and 2015, the Deciphering Developmental Disorders (DDD) study 
recruited ~13,500 patients suffering from developmental disorders with no genetic diagnosis and 
sequenced probands alongside their parents (Fitzgerald 2015). Only six years later, a follow-up 
assessment considered a small subset of the initial DDD study and found disease-specific 
treatment is ongoing for several probands. Further, in addition to improvements in patient care, 
the study found significant psychosocial improvements for parents of affected children, with 
“relief” commonly cited as an impact of receiving a genetic diagnosis (Copeland 2021). 
Advancements in genetic sequencing have already provided innumerable benefits to patients and 
their families.  
 Fortunately, the continuous addition of new genetic and medical records to clinical 
genetic and Mendelian disease databases, such as ClinVar and OMIM, will continue to allow 
researchers to generate new insights on prior genetic findings and to leverage existing analytical 
approaches on expanding datasets to provide patients with previously unidentified genetic 
diagnoses. In chapter 1, we find the ratio of missense variants to predicted loss-of-function 
variants in autosomal dominant disease genes can identify a set of genes likely to act through a 
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gain-of-function mechanism. Further, 19 of these likely gain-of-function genes are highly 
tolerant to loss-of-function mutations and are known to be in the druggable genome, making 
them well suited for therapeutic testing of known inhibitors in in vitro systems. Identifying likely 
gain-of-function genes was possible with as few as 10 known likely pathogenic / pathogenic 
variants. Importantly, disease-causing autosomal dominant genes with hundreds or thousands of 
pathogenic variants are likely to have been extensively studied in vitro and often the direction of 
effect of mutation will often already be known. Alternatively, rare disease variants that have just 
passed, or soon will pass, the threshold of 10 known reported disease-causing variants may 
especially benefit from the work in chapter 1. Investigators may be more interested in 
participating in rare disease research if the gene of interest is already hypothesized to be tractable 
for therapeutic development. 
 DNA-sequencing and downstream large clinical genetic databases have already 
significantly impacted lives of patients and families and additional genomic data will allow for 
continued advancement. More recent advancements in RNA-sequencing may be beginning to 
follow a similar trend. Over the next decade, transcriptomic findings may translate to improved 
patient outcomes for developmental disease, including neurodevelopmental disorders (‘NDDs’), 
as more transcriptomic analyses are published and aggregated. One potential avenue in which 
transcriptomic analyses can be used to improve patient outcomes is through model 
characterization and validation.  
 Generating therapeutics for CNS disorders has historically been challenging, with 
psychiatric disorders being especially difficult to translate from phase I trials to FDA approval 
(table 1). Animal models for NDDs in particular have encountered significant obstacles, due to 
some combination of lack of disease-relevant phenotypes, muted presentation and therapeutic 
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strategies that don’t translate from laboratory bench to bedside. More recently, human stem cell-
derived models of neurodevelopment have emerged as a promising alternative to animal studies. 
Confoundingly, human in vitro models have their own limitations with neurons often differing 
substantially from their in vivo counterparts and displaying stunted diversity of cell types. 
 Importantly, transcriptomic analyses have been effectively utilized to better characterize 
the similarity and differences of in vitro and in vivo neurons. Using RNA-sequencing, 
researchers can identify disease signatures for different populations of cells. Further, more recent 
next generation sequencing advancements such as single-cell sequencing allow investigators to 
identify dysregulation of genes for specific cellular subtypes. Due to these improvements, 
investigators have been able to compare transcriptomic signatures of in vitro models and in vivo 
samples. Disease signatures in human stem cell-derived neurons can be compared to the 
transcriptomic dysregulation seen in animal models or human tissue, including fetal and 
postmortem samples. Surprisingly, despite these advancements, robust, transcriptome level 
analyses of how correlated the signature of an in vitro human model is to an in vivo model are 
exceedingly rare.  
 In chapter 2, we show the potential, and significant limitations, of using a transcriptomic 
reversal approach to developing targeted therapeutics. When comparing the pseudobulk 
signature of 6.5-week- old human cortical organoids (‘hCOs’) to bulk RNA-sequencing of 
embryonic and perinatal mice, we show evidence of consistent transcriptomic perturbation 
between HNRNPU+/- hCOs and mutant embryonic mice. Critically, this similarity is absent at 
perinatal time points. In fact, downregulated ribosomal genes in organoids are upregulated in 
perinatal mouse models of HNRNPU deficiency. Further, we show neuronal populations in two 
distinct isogenic HNRNPU+/- lines show reduced burden of dysregulated genes compared to 
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precursor populations, introducing preliminary evidence that human models have development 
diversity in disease signatures. While generating additional sequencing data for hCOs at 
significantly older ages would be required to better understand disease etiology in a human 
system and determine whether or not developmental divergence in transcriptomic signature of 
mice is recapitulated, these findings suggest therapeutic strategies reliant on transcriptomic 
reversal may be heavily confounded by the necessity to reverse the signature of specific sets of 
cells at very specific developmental timepoints. Importantly, we only considered two murine 
time points and a single organoid age. Characterizing transcriptomic dysregulation at more time 
points in either human or mouse models may show if, or when, the transcriptomic signature of 
HNRNPU deficiency stabilizes. Further, we considered a single genetic disorder and 
transcriptomic dysregulation in alternative neurodevelopmental disorders may not be similarly 
confounded and may be better suited for therapeutic reversal stratagems. 
 Additionally, transcriptomic comparisons can elucidate disease processes and may be 
used to validate the potential of human-specific models of disease. We show that transcriptomic 
dysregulation in a human model of HNRNPU deficiency is not predominantly driven by model 
system and is partially reproduced in an in vivo system. The relationship between transcriptomic 
disruption and patient phenotypes will not always be straightforward. Hypothetically, certain 
aspects of transcriptomic dysregulation may in fact be protective. Alternatively, changes at the 
RNA-level will not always lead to downstream differences at the protein or functional level. 
Thus, functional assays capable of identifying disease-relevant phenotypes may improve 
confidence that transcriptomic changes translate to patient phenotypes. 
 In chapter 3, we utilize MEAs to assess synchrony in mouse and human in vitro models. 
In chapter 3a, we show that incorporating the distance between electrodes into algorithms that 
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quantify synchrony in vitro allows for the identification of novel, complementary phenotypes in 
distinct mouse models of NDDs. Importantly, all analyses included mice modeling epileptic 
encephalopathies where synchrony differences are present in vivo. However, topological 
analyses in MEAs still generate phenotypes that cannot be directly tied to in vivo EEGs or patient 
phenotypes. Whether or not there is a relationship between synchrony of neighboring electrodes 
and synchrony differences in EEGs in patients, or even living mice, is unknown. Further, MEAs 
exhibit high levels of variability and many of the MEA phenotypes identified or discussed in 
chapter 3a are modest in effect, which limits the throughput of MEA systems and may confound 
therapeutic development for certain disease models.  
 We then considered whether or not we could generate a paradigm for studying excitatory 
/ inhibitory (‘E/I’) imbalance in a human system using MEAs. E/I imbalance has been 
hypothesized to underlie a wide array of NDDs and many human stem cell-derived neuron 
protocols tend to be heavily enriched for either excitatory or inhibitory neurons. We posited that 
human model systems with more physiological proportions of excitatory and inhibitory neurons 
may encounter similar variability and effect size concerns, yet their species-specificity would 
lead to functional phenotypes more relevant to patients. Unfortunately, over 90 days the 
inhibitory neuron populations failed to functionally mature in aggregate, with proportional and 
inhibitory networks remaining heavily enriched for early developmental genes, but not more 
mature canonical markers or inhibitory synaptic proteins, when compared to excitatory networks. 
Consistent with synaptic findings, proportional networks did not materially differ in synchrony 
profiles on MEAs compared to excitatory networks. Thus, we suggest that for human MEA 
models to effectively model NDDs with E/I imbalance, improvements in differentiation 
protocols or protracted timelines may be required. 
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Genomic and transcriptomic findings, alongside constantly iterating differentiation 
paradigms and electrophysiological techniques, provide significant hope for improvements of 
functional assessments of synchrony in vitro. Identifying genes or processes implicated in 
neurogenic and synaptogenic processes can directly translate to new differentiation paradigms. 
Media formulations and bioreactors to maintain neuronal networks in vitro are constantly being 
updated and may further improve the ability to generate functionally mature networks in shorter 
time frames. Further, MEAs are only one of several techniques to assess synchrony in vitro. 
Alternative medium- to high-throughput technologies are concurrently being utilized as tools for 
CNS pharmacological stratagems, including Calcium imaging, voltage-sensing dyes and robotic 
patch-clamp systems (Accardi 2016).  
In summary, we addressed three potential bottle necks in transitioning from the 
identification of pathogenic variant to generating therapeutics for patients. In chapter 1, we 
present a method capable of identifying genes most likely to generate addressable signals in 
vitro. In chapter 2, we utilized cross-species comparisons of transcriptomic signatures and find 
HNRNPU+/- hCOs have dysregulation consistent with in vivo embryonic mice, but not perinatal 
mice. Finally, in chapter 3 we introduce novel topological tools to identify synchrony phenotypes 
in vitro, while underscoring the current limitations of mouse and human MEA models. Taken 
together, the work within this thesis begins to show the outlines of a potential holistic approach 
to moving from pathogenic variant to therapeutic candidate in vitro. Thoughtful gene selection is 
followed by identifying and reversing transcriptomic phenotypes in an appropriate model system. 




 Critically, the work within this thesis shows considerable challenges remain in generating 
effective therapeutics for patients with genetic NDDs. Identifying the genetic cause of disease 
allows researchers to study a similar genetic perturbation in animal systems and/or human in 
vitro models. However, all such model systems generate cells that are distinct from those in 
patients, due to either a lack of species-specificity or complexities in generating neurons in vitro. 
While model systems don’t generate identical cell types, certain genetic perturbations may lead 
to similar dysregulation across systems, as described in chapter 2. However, even in such 
situations, biomarkers of disease may be confounded by developmental age and cellular subtype. 
Further, even if biomarkers identified in model systems are replicated in patients, such 
biomarkers may not be causal of the life-altering phenotypes experienced by patients. Certain 
biomarkers may potentially be protective or superfluous and correction may not be therapeutic. 
Thus, connecting biomarkers of disease to functional phenotypes in model systems may be an 
essential step in therapeutic development stratagems. Identifying functional phenotypes in vitro 
has proved challenging, with potentially saturating levels of synchrony in murine MEAs and 
extended developmental timelines required to mature human networks. Improving upon 
paradigms to identify functional phenotypes in vitro may be an essential innovation in order to 
effectively develop therapies in the future. Reversing aberrant patterns of activity that directly 
relate to phenotypes seen in patient EEGs will likely be incredibly challenging to; however, 
innovations that allow for such an approach may dramatically improve the capacity of in vitro 
models to identify therapeutics. Without improvements in identifying patient-relevant functional 
phenotypes, in vivo animal models, including rodent models, may be superior systems to develop 
effective therapeutics capable of ameliorating symptoms of NDDs, as they allow for direct 
assessment of certain behavioral and seizure phenotypes. In instances where in vivo mouse 
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models have consistently failed to generate therapeutics, such as Fragile X syndrome, the benefit 
of species-specificity of human in vitro models may outweigh the limitations of such systems. In 
such circumstances, reversing elements of transcriptomic dysregulation in appropriate cell types 
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